Healthcare Services (HCSG) 10-Q26 Jul 242024 Q2 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2024	Jul. 24, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	0-12015
Entity Registrant Name	HEALTHCARE SERVICES GROUP, INC.
Entity Incorporation, State Code	PA
I.R.S. Employer Identification No.	23-2018365
Entity Address, Address Line One	3220 Tillman Drive
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Bensalem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19020
City Area Code	215
Local Phone Number	639-4274
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HCSG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		73,383,184
Entity Central Index Key	0000731012
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 26,430	$ 54,330
Restricted cash equivalents	3,117	0
Marketable securities, at fair value	79,134	93,131
Restricted marketable securities, at fair value	22,022	0
Accounts and notes receivable, less allowance for doubtful accounts of $112,133 and $87,250 as of June 30, 2024 and December 31, 2023, respectively	398,884	383,509
Inventories and supplies	17,857	18,479
Prepaid expenses and other assets	25,768	22,247
Total current assets	573,212	571,696
Property and equipment, net	29,840	28,774
Goodwill	75,529	75,529
Other intangible assets, less accumulated amortization of $37,899 and $36,557 as of June 30, 2024 and December 31, 2023, respectively	10,785	12,127
Notes receivable — long–term portion, less allowance for doubtful accounts of $3,152 and $4,449 as of June 30, 2024 and December 31, 2023, respectively	20,871	24,832
Deferred compensation funding, at fair value	46,043	40,812
Deferred tax assets	38,917	35,226
Other long-term assets	4,505	1,656
Total assets	799,702	790,652
Current liabilities:
Accounts payable	72,220	83,224
Accrued payroll and related taxes	57,014	56,142
Other accrued expenses and current liabilities	22,987	21,179
Borrowings under line of credit	30,000	25,000
Income taxes payable	4,279	7,201
Deferred compensation liability — short-term	1,390	1,501
Accrued insurance claims	21,593	22,681
Total current liabilities	209,483	216,928
Accrued insurance claims — long-term	61,209	61,697
Deferred compensation liability — long-term	46,201	41,186
Lease liability — long-term	10,662	11,235
Other long-term liabilities	724	2,990
Commitments and contingencies (Note 15)
STOCKHOLDERS’ EQUITY:
Common stock, $0.01 par value; 200,000 shares authorized; 76,533 and 76,329 shares issued, and 73,383 and 73,341 shares outstanding as of June 30, 2024 and December 31, 2023, respectively	765	763
Additional paid-in capital	314,146	310,436
Retained earnings	198,595	185,010
Accumulated other comprehensive loss, net of taxes	(2,617)	(1,844)
Common stock in treasury, at cost, 3,150 and 2,988 shares as of June 30, 2024 and December 31, 2023, respectively	(39,466)	(37,749)
Total stockholders’ equity	471,423	456,616
Total liabilities and stockholders’ equity	$ 799,702	$ 790,652

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts, current	$ 112,133	$ 87,250
Accumulated amortization of other intangible assets	37,899	36,557
Allowance for doubtful accounts, noncurrent	$ 3,152	$ 4,449
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock authorized (in shares)	200,000,000	200,000,000
Common stock issued (in shares)	76,533,000	76,329,000
Common stock outstanding (in shares)	73,383,000	73,341,000
Common stock in treasury (in shares)	3,150,000	2,988,000

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenues	$ 426,288	$ 418,931	$ 849,721	$ 836,161
Operating costs and expenses:
Costs of services provided	384,742	368,204	743,653	730,583
Selling, general and administrative expense	44,437	41,429	91,348	81,476
Other income (expense):
Investment and other income, net	2,621	3,551	8,320	6,653
Interest expense	(1,716)	(1,915)	(3,712)	(3,666)
(Loss) income before taxes	(1,986)	10,934	19,328	27,089
Income tax (benefit) provision	(198)	2,680	5,807	7,164
Net (loss) income	$ (1,788)	$ 8,254	$ 13,521	$ 19,925
Per share data:
Basic (loss) earnings per common share (in dollars per share)	$ (0.02)	$ 0.11	$ 0.18	$ 0.27
Diluted (loss) earnings per common share (in dollars per share)	$ (0.02)	$ 0.11	$ 0.18	$ 0.27
Weighted average number of common shares outstanding:
Basic (in shares)	73,853	74,478	73,889	74,488
Diluted (in shares)	73,853	74,567	74,048	74,543
Comprehensive (loss) income:
Net (loss) income	$ (1,788)	$ 8,254	$ 13,521	$ 19,925
Other comprehensive (loss) income
Unrealized (loss) gain on available-for-sale marketable securities, net of taxes	(445)	(860)	(773)	347
Total comprehensive (loss) income	$ (2,233)	$ 7,394	$ 12,748	$ 20,272

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows used in operating activities
Net (loss) income	$ 13,521	$ 19,925
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	7,210	7,315
Bad debt provision	36,643	18,170
Deferred income taxes	(3,485)	42
Share-based compensation expense	4,597	4,409
Amortization of premium on marketable securities	795	1,073
Unrealized gain on deferred compensation fund investments	(5,388)	(3,790)
Changes in other long-term liabilities	(334)	(249)
Net loss on disposals of property and equipment	405	387
Changes in operating assets and liabilities:
Accounts and notes receivable	(48,056)	(59,585)
Inventories and supplies	623	1,188
Prepaid expenses and other assets	(3,491)	7,824
Deferred compensation funding	157	262
Accounts payable and other accrued expenses	(15,695)	(9,337)
Accrued payroll, accrued and withheld payroll taxes	1,862	(461)
Income taxes payable	(2,921)	(4,859)
Accrued insurance claims	(1,576)	5,104
Deferred compensation liability	5,419	3,695
Net cash used in operating activities	(9,714)	(8,887)
Cash flows used in investing activities:
Disposals of property and equipment	150	85
Additions to property and equipment	(3,510)	(2,097)
Acquisition of equity method investment	(2,750)	0
Purchases of marketable securities	(37,880)	0
Sales of marketable securities	27,951	1,375
Net cash used in investing activities	(16,039)	(637)
Cash flows from financing activities:
Purchases of treasury stock	(3,000)	(2,223)
Proceeds from short-term borrowings	5,000	15,000
Payments of statutory withholding on net issuance of restricted stock units	(1,030)	(870)
Net cash from financing activities	970	11,907
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents	(24,783)	2,383
Cash, cash equivalents and restricted cash equivalents at beginning of the period	54,330	26,279
Cash, cash equivalents and restricted cash equivalents at end of the period	$ 29,547	$ 28,662

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss, net of taxes	Retained Earnings	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2022		76,161
Beginning balance at Dec. 31, 2022	$ 418,279	$ 762	$ 302,304	$ (3,477)	$ 146,602	$ (27,912)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	11,671				11,671
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes	1,207			1,207
Shares issued in connection with equity incentive plans, net of taxes (in shares)		167
Shares issued in connection with equity incentive plans, net of taxes	(870)	$ 1	(871)
Share-based compensation expense	1,973		1,973
Purchases of treasury stock	(2,223)					(2,223)
Shares issued for Deferred Compensation Plan, net	475		307			168
Shares issued for Employee Stock Purchase Plan	1,135		(139)			1,274
Other (in shares)		1
Other	19		8		11
Ending balance (in shares) at Mar. 31, 2023		76,329
Ending balance at Mar. 31, 2023	431,666	$ 763	303,582	(2,270)	158,284	(28,693)
Beginning balance (in shares) at Dec. 31, 2022		76,161
Beginning balance at Dec. 31, 2022	418,279	$ 762	302,304	(3,477)	146,602	(27,912)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	19,925
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes	347
Ending balance (in shares) at Jun. 30, 2023		76,329
Ending balance at Jun. 30, 2023	441,339	$ 763	305,853	(3,130)	166,544	(28,691)
Beginning balance (in shares) at Mar. 31, 2023		76,329
Beginning balance at Mar. 31, 2023	431,666	$ 763	303,582	(2,270)	158,284	(28,693)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	8,254				8,254
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes	(860)			(860)
Share-based compensation expense	2,278		2,278
Shares issued for Deferred Compensation Plan, net	(5)		(7)			2
Other	6				6
Ending balance (in shares) at Jun. 30, 2023		76,329
Ending balance at Jun. 30, 2023	$ 441,339	$ 763	305,853	(3,130)	166,544	(28,691)
Beginning balance (in shares) at Dec. 31, 2023	73,341	76,329
Beginning balance at Dec. 31, 2023	$ 456,616	$ 763	310,436	(1,844)	185,010	(37,749)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	15,309				15,309
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes	(328)			(328)
Shares issued in connection with equity incentive plans, net of taxes (in shares)		204
Shares issued in connection with equity incentive plans, net of taxes	(1,030)	$ 2	(1,032)
Share-based compensation expense	2,444		2,444
Shares issued for Deferred Compensation Plan, net	519		448			71
Shares issued for Employee Stock Purchase Plan	989		(216)			1,205
Other	62				62
Ending balance (in shares) at Mar. 31, 2024		76,533
Ending balance at Mar. 31, 2024	$ 474,581	$ 765	312,080	(2,172)	200,381	(36,473)
Beginning balance (in shares) at Dec. 31, 2023	73,341	76,329
Beginning balance at Dec. 31, 2023	$ 456,616	$ 763	310,436	(1,844)	185,010	(37,749)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	13,521
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes	$ (773)
Ending balance (in shares) at Jun. 30, 2024	73,383	76,533
Ending balance at Jun. 30, 2024	$ 471,423	$ 765	314,146	(2,617)	198,595	(39,466)
Beginning balance (in shares) at Mar. 31, 2024		76,533
Beginning balance at Mar. 31, 2024	474,581	$ 765	312,080	(2,172)	200,381	(36,473)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(1,788)				(1,788)
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes	(445)			(445)
Share-based compensation expense	2,075		2,075
Purchases of treasury stock	(3,000)					(3,000)
Shares issued for Deferred Compensation Plan, net	(2)		(9)			7
Other	$ 2				2
Ending balance (in shares) at Jun. 30, 2024	73,383	76,533
Ending balance at Jun. 30, 2024	$ 471,423	$ 765	$ 314,146	$ (2,617)	$ 198,595	$ (39,466)

Description of Business and Sig

Description of Business and Significant Accounting Policies	6 Months Ended
Description of Business and Significant Accounting Policies	Jun. 30, 2024
Accounting Policies [Abstract]
Description of Business and Significant Accounting Policies	Note 1—Description of Business and Significant Accounting Policies Nature of Operations Healthcare Services Group, Inc. (the “Company”) provides management, administrative and operating expertise and services to the housekeeping, laundry, linen, facility maintenance and dietary service departments predominantly to clients within the healthcare industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals located throughout the United States. Although the Company does not directly participate in any government reimbursement programs, the Company’s customers receive government reimbursements related to Medicare and Medicaid. Therefore, the Company’s customers are directly affected by any legislation relating to Medicare and Medicaid reimbursement programs. The Company provides services primarily pursuant to full service agreements with its customers. In such agreements, the Company is responsible for the day-to-day management of its employees located at the customers’ facilities, as well as for the provision of certain supplies. The Company also provides services on the basis of management-only agreements for a limited number of customers. In a management-only agreement, the Company provides management and supervisory services while the customer facility retains payroll responsibility for the non-supervisory staff. The agreements with customers typically provide for a renewable one year service term, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days. The Company is organized into two reportable segments: housekeeping, laundry, linen and other services (“Housekeeping”), and dietary department services (“Dietary”). Housekeeping consists of managing the customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of a customer’s facility, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at a customer facility. Dietary consists of managing the customers’ dietary departments, which are principally responsible for food purchasing, meal preparation and dietitian professional services, which includes the development of menus that meet residents’ dietary needs. Unaudited Interim Financial Data The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and the requirements of Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations and cash flows. However, in the Company’s opinion, all adjustments which are of a normal recurring nature and are necessary for a fair presentation have been reflected in these consolidated financial statements. The balance sheet shown in this report as of December 31, 2023 has been derived from the audited financial statements for the year ended December 31, 2023. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for any future period. Use of Estimates in Financial Statements In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Healthcare Services Group, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Cash and Cash Equivalents and Restricted Cash Equivalents Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as short-term, highly liquid investments with a maturity of three months or less at time of purchase that are readily convertible into cash and have insignificant interest rate risk. Restricted cash equivalents represent highly liquid investments held in a trust account as collateral for certain insurance coverages the Company obtained from a third-party insurance carrier. The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets to the amount reported in the Consolidated Statements of Cash Flows. June 30, 2024 June 30, 2023 (in thousands) Cash and cash equivalents $ 26,430 $ 28,662 Restricted cash equivalents 1 3,117 — Total cash and cash equivalents and restricted cash equivalents $ 29,547 $ 28,662 1. On February 2, 2024, the Company entered into a Collateral Trust Agreement with the Company’s third-party insurer and a trustee whereby investments or money market funds are held in a trust account to benefit the insurer and are restricted for that purpose. Restricted cash equivalents represent funds invested in money market accounts as of June 30, 2024. The trust account was set up in conjunction with a reduction in the Company’s letter of credit collateral obligation for insurance obligations. Accounts and Notes Receivable Accounts and notes receivable consist of Housekeeping and Dietary segment trade receivables from contracts with customers. The Company’s payment terms with customers for services provided are defined within each customer’s service agreement. Accounts receivable are considered short term assets as the Company does not grant payment terms greater than one year. Accounts receivable initially are recorded at the transaction amount and are recorded after the Company has an unconditional right to payment where only the passage of time is required before payment is received. Each reporting period, the Company evaluates the collectability of outstanding receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit loss. Additions to the allowance for doubtful accounts are made by recording a charge to bad debt expense reported in costs of services provided. Notes receivable are initially recorded when accounts receivable are transferred into a promissory note and are recorded as an alternative to accounts receivable to memorialize an unqualified promise to pay a specific sum, typically with interest, in accordance with a defined payment schedule. The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however most promissory notes mature over 1 to 4 years. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses. Allowance for Doubtful Accounts Management utilizes financial modeling to determine an allowance that reflects its best estimate of the lifetime expected credit losses on accounts and notes receivable which is recorded to offset the receivables. Modeling is prepared after considering historical experience, current conditions and reasonable and supportable economic forecasts to estimate lifetime expected credit losses. Accounts and notes receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense when received. Inventories and Supplies Inventories and supplies include housekeeping, linen and laundry supplies, as well as food provisions and supplies. Non-linen inventories and supplies are stated on a first-in, first-out (“FIFO”) basis, and reduced as deemed necessary to approximate the lower of cost or net realizable value. Linen supplies are amortized on a straight-line basis over their estimated useful life of 24 months. Revenue Recognition The Company recognizes revenue from contracts with customers when or as the promised goods and services are provided to customers. Revenues are reported net of sales taxes that are collected from customers and remitted to taxing authorities. The amount of revenue recognized by the Company is based on the expected value of consideration to which the Company is entitled in exchange for providing the contracted goods and services and when it is probable that the Company will collect substantially all of such consideration. Leases The Company records assets and liabilities on the Consolidated Balance Sheets to recognize the rights and obligations arising from leasing arrangements with contractual terms greater than 12 months. A leasing arrangement includes any contract which entitles the Company to the right of use of an identified tangible asset where there are no restrictions as to the direction of use of the asset and the Company obtains substantially all of the economic benefits from the right of use. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, income tax expense or benefits are recognized for the amount of taxes payable or refundable for the current period. The Company accrues for probable tax obligations as required based on facts and circumstances in various regulatory environments. In addition, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. When appropriate, valuation allowances are recorded to reduce deferred tax assets to amounts for which realization is more likely than not. Uncertain income tax positions taken or expected to be taken in tax returns are reflected within the Company’s consolidated financial statements based on a recognition and measurement process. (Loss) Earnings per Common Share Basic (loss) earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted (loss) earnings per common share is computed using the weighted-average number of common shares outstanding and dilutive common shares, such as those issuable upon exercise of stock awards. Diluted loss per common share excludes dilutive potential common shares from the calculation, as their inclusion would be anti-dilutive. Share-Based Compensation The Company estimates the fair value of share-based awards on the date of grant using a Black-Scholes valuation model for stock options, using a Monte Carlo simulation for performance restricted stock units, and using the share price on the date of grant for restricted stock units and deferred stock units. The value of the award is recognized ratably as an expense in the Company’s Consolidated Statements of Comprehensive (Loss) Income over the requisite service periods with adjustments made for forfeitures as they occur. Goodwill and Other Intangible Assets Goodwill represents the excess of cost over the fair value of net assets of acquired businesses. Management reviews the carrying value of goodwill annually during the fourth quarter to assess for impairment or more often if events or circumstances indicate that the carrying value may exceed its estimated fair value. Other intangible assets are amortized on a straight-line basis over their respective useful lives. No impairment loss was recognized on the Company’s goodwill or other intangible assets during the six months ended June 30, 2024 or 2023. Authorized Shares of Common Stock On June 18, 2024, the Company amended its Restated Articles of Incorporation to increase the number of authorized shares of common stock available for issuance from 100 million to 200 million, which was previously approved by a majority of the Company’s shareholders. Investments in Equity Securities The Company accounts for investments in equity securities using the equity method when the Company determines that it can exercise significant influence over the investee. The Company accounts for investments in equity securities at fair value when the Company determines that it cannot exercise significant influence over the investee. During the six months ended June 30, 2024, the Company invested $2.8 million for a 25% ownership share in a health care technology company which specializes in the long-term and acute care markets which was accounted for as an equity method investment. Investments in equity securities are recorded within “Other long-term assets” in the Company’s Consolidated Balance Sheets. The Company’s proportionate share of earnings or losses of the investee are recorded within “Investment and other income, net” on the Company's Consolidated Statements of Comprehensive (Loss) Income. The Company elects to record its proportionate share of earnings or losses in equity method investments using a three-month lag based on the most recently available financial statements. Concentrations of Credit Risk The Company’s financial instruments that are subject to credit risk are cash and cash equivalents, restricted cash equivalents, marketable securities, restricted marketable securities, deferred compensation funding and accounts and notes receivable. At June 30, 2024, the majority of the Company’s cash and cash equivalents, restricted cash equivalents, marketable securities and restricted marketable securities were held in two large financial institutions located in the United States. At December 31, 2023, the majority were held in one large financial institution located in the United States. The Company’s marketable securities and restricted marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. The Company’s deferred compensation funding consists of fund and money market investments all of which are highly liquid and held in a trust account. The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the Company’s customers participate. As a result, the Company may not realize the full effects such programs may have on the Company’s customers until such new legislation or changes in existing regulations are fully implemented and governmental agencies issue applicable regulations or guidance. Significant Customer For the three months ended June 30, 2024 and 2023, Genesis Healthcare, Inc. (“Genesis”) accounted for $37.9 million, or 8.9%, and $47.6 million, or 11.4%, of the Company’s consolidated revenues, respectively. For the six months ended June 30, 2024 and 2023, Genesis accounted for $76.7 million, or 9.0%, and $95.7 million, or 11.4%, of the Company's consolidated revenues, respectively. Although the Company expects to continue its relationship with Genesis, there can be no assurance thereof. Revenues generated from Genesis were included in both operating segments previously mentioned. Any extended discontinuance of revenues, or significant reduction, from this customer could, if not replaced, have a material impact on our operations. In addition, if Genesis fails to abide by current payment terms, it could increase our accounts and notes receivable, net balance and have a material adverse effect on our financial condition, results of operations, and cash flows. No other single customer or customer group represented more than 10% of our consolidated revenues for the three and six months ended June 30, 2024 and 2023. Employee Retention Credit On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). One provision within the CARES Act provided an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable tax credit against the employer share of Social Security tax equal to 50% of the qualified wages paid to employees from March 13, 2020 through December 31, 2020. The ERC was subsequently expanded in 2021 for employers to claim a refundable tax credit for 70% of the qualified wages paid to employees from January 1, 2021 through September 30, 2021. The Company accounted for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. During the quarter ended June 30, 2023, the Company filed a claim for the ERC for qualified wages paid in 2020 and 2021 and through July 26, 2024 has yet to receive any refunds or receive any correspondence from the IRS regarding the ERC filing. The Company believes that there is not reasonable assurance that any receipt of credits will be obtained and therefore has not recognized any amounts related to the ERC in the accompanying consolidated financial statements. Should reasonable assurance over receipt of and compliance with terms of the ERC credits be obtained in future periods, the Company would recognize such amounts as an offset to expense within “Costs of services provided” on the Consolidated Statements of Comprehensive (Loss) Income. In the event the Company obtains a refund in future periods, such refunds would be subject to IRS audit under the applicable statute of limitations. Reclassifications Prior period line items in the Consolidated Statements of Stockholders’ Equity have been revised to conform with current period presentation.

Revision of Prior Period Financ

Revision of Prior Period Financial Statements	6 Months Ended
Revision of Prior Period Financial Statements	Jun. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Revision of Prior Period Financial Statements	Note 2 — Revision of Prior Period Financial Statements As previously disclosed in Note 2 to the Company’s consolidated financial statements as of and for the year ended December 31, 2023, the Company identified a prior period accounting error related to the Company’s estimate for accrued payroll, and specifically accrued vacation that was concluded to not be material to the Company’s previously reported consolidated financial statements or unaudited interim condensed consolidated financial statements. The Company assessed the quantitative and qualitative factors associated with the foregoing error in accordance with SEC Staff Accounting Bulletin (“SAB”) No. 99 and 108, Materiality, codified in Accounting Standards Codification (“ASC”) 250, Presentation of Financial Statements, and concluded that the error was not material to any of the Company’s previously reported annual or interim consolidated financial statements. Notwithstanding this conclusion, the Company corrected the error by revising the consolidated 2023 accompanying consolidated interim financial statements to give effect to the correction of the error. The effect of the correction of the error noted above on the Company’s Consolidated Statements of Comprehensive (Loss) Income for the three and six months ended June 30, 2023 is as follows: Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 As reported Adjustment Revised As reported Adjustment Revised (in thousands, except per share amounts) Costs of services provided $ 367,728 $ 476 $ 368,204 $ 728,706 $ 1,877 $ 730,583 Income before taxes $ 11,410 $ (476) $ 10,934 $ 28,966 $ (1,877) $ 27,089 Income tax provision $ 2,812 $ (132) $ 2,680 $ 7,684 $ (520) $ 7,164 Net income $ 8,598 $ (344) $ 8,254 $ 21,282 $ (1,357) $ 19,925 Basic earnings per common share $ 0.12 $ (0.01) $ 0.11 $ 0.29 $ (0.02) $ 0.27 Diluted earnings per common share $ 0.12 $ (0.01) $ 0.11 $ 0.29 $ (0.02) $ 0.27

Revenue

Revenue	6 Months Ended
Revenue	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	Note 3—Revenue The Company presents its consolidated revenues disaggregated by reportable segment, as Management evaluates the nature, amount, timing and uncertainty of the Company’s revenues by segment. Refer to Note 13—Segment Information herein as well as the information below regarding the Company’s reportable segments. Housekeeping Housekeeping accounted for $381.6 million and $384.3 million of the Company’s consolidated revenues for the six months ended June 30, 2024 and 2023, respectively, which represented approximately 44.9% and 46.0% of the Company’s revenues in each respective period. Housekeeping services include managing customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of the customers’ facilities, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at the customers’ facilities. Upon beginning service with a customer facility, the Company will typically hire and train the employees previously employed by such facility and assign an on-site manager to supervise and train the front-line personnel and coordinate housekeeping services with other facility support functions in accordance with customer requests. Such management personnel also oversee the execution of various cost and quality control procedures including continuous training and employee evaluation. Dietary Dietary services accounted for $468.2 million and $451.8 million of the Company’s consolidated revenues for the six months ended June 30, 2024 and 2023, respectively, which represented approximately 55.1% and 54.0% of the Company’s revenues in each respective period. Dietary services consist of managing customers’ dietary departments which are principally responsible for food purchasing, meal preparation and professional dietitian services, which include the development of menus that meet the dietary needs of residents. On-site management is responsible for all daily dietary department activities, with regular support provided by a District Manager specializing in dietary services. The Company also offers clinical consulting services to facilities which if contracted is a service bundled within the monthly service provided to customers. Upon beginning service with a customer facility, the Company will typically hire and train the employees previously employed by such facility and assign an on-site manager to supervise and train the front-line personnel and coordinate dietitian services with other facility support functions in accordance with customer requests. Such management personnel also oversee the execution of various cost and quality control procedures including continuous training and employee evaluation. Revenue Recognition The Company’s revenues are derived from contracts with customers. The Company recognizes revenue to depict the transfer of promised goods and services to customers in amounts that reflect the consideration to which the Company is entitled in exchange for those goods and services. The Company’s costs of obtaining contracts are not material. The Company performs services and provides goods in accordance with its contracts with its customers. Such contracts typically provide for a renewable one year service term, cancellable by either party upon 30 to 90 days’ notice, after an initial period of 60 to 120 days. A performance obligation is the unit of account under ASC 606 and is defined as a promise in a contract to transfer a distinct good or service to the customer. The Company’s Housekeeping and Dietary contracts relate to the provision of bundles of goods, services or both, which represent a series of distinct goods and services that are substantially the same and that have the same pattern of transfer to the customer. The Company accounts for the series as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. Revenue is recognized using the output method, which is based upon the delivery of goods and services to the customers’ facilities. In limited cases, the Company provides goods, services or both before the execution of a written contract. In these cases, the Company defers the recognition of revenue until a contract is executed. The amount of such deferred revenue was less than $0.1 million as of June 30, 2024 and December 31, 2023. All revenue amounts deferred as of December 31, 2023 were subsequently recognized as revenue during the six months ended June 30, 2024. The transaction price is the amount of consideration to which the Company is entitled in exchange for transferring promised goods or services to its customers. The transaction price does not include taxes assessed or collected. The Company’s contracts detail the fees that the Company charges for the goods and services it provides. For certain contracts which contain a variable component to the transaction price, the Company is required to make estimates of the amount of consideration to which the Company will be entitled based on variability in resident and patient populations serviced, product usage, quantities consumed or history of implicit price concessions. The Company recognizes revenue related to such estimates when the Company determines that it is probable there will not be a significant reversal in the amount of revenue recognized. In instances where variable consideration exists and management’s estimate of variable consideration changes in subsequent periods, resulting in a change in transaction price, the Company records an adjustment to revenue on a cumulative catch-up basis. The Company’s contracts generally do not contain significant financing components as payment terms are less than one year. The Company allocates the transaction price to each performance obligation noting that the bundle of goods, services or goods and services provided under each Housekeeping and Dietary contract represents a single performance obligation that is satisfied over time. The Company recognizes the related revenue when it satisfies the performance obligation by transferring a bundle of promised goods, services or both to a customer. Such recognition is on a monthly or weekly basis, as goods are provided and services are performed. In some cases, the Company requires customers to pay in advance for goods and services to be provided. As of June 30, 2024, the value of the contract liabilities associated with customer prepayments was $1.3 million. As of December 31, 2023, the value of the contract liabilities associated with customer prepayments was $3.2 million. The Company recognized $1.9 million of revenue during the six months ended June 30, 2024 which was recorded as a contract liability on December 31, 2023. Transaction Price Allocated to Remaining Performance Obligations The Company recognizes revenue as it satisfies the performance obligations associated with contracts with customers which, due to the nature of the goods and services provided by the Company, are satisfied over time. Contracts may contain transaction prices that are fixed, variable or both. The Company’s contracts with customers typically provide for an initial term of one year, with renewable one year service terms, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days. The Company has elected to apply the practical expedient that permits exclusion of information about the remaining performance obligations with original expected durations of one year or less which applies to all of the Company’s remaining performance obligations as of June 30, 2024.

Accounts and Notes Receivable

Accounts and Notes Receivable	6 Months Ended
Accounts and Notes Receivable	Jun. 30, 2024
Receivables [Abstract]
Accounts and Notes Receivable	Note 4—Accounts and Notes Receivable The Company’s accounts and notes receivable balances consisted of the following: June 30, 2024 December 31, 2023 (in thousands) Short-term Accounts and notes receivable $ 511,017 $ 470,759 Allowance for doubtful accounts (112,133) (87,250) Total net short-term accounts and notes receivable $ 398,884 $ 383,509 Long-term Notes receivable $ 24,023 $ 29,281 Allowance for doubtful accounts (3,152) (4,449) Total net long-term notes receivable $ 20,871 $ 24,832 Total net accounts and notes receivable $ 419,755 $ 408,341 The Company makes credit decisions on a case-by-case basis after reviewing a number of qualitative and quantitative factors related to the specific customer as well as current industry variables that may impact that customer. There are a variety of factors that impact a customer’s ability to pay in accordance with the Company’s contracts. These factors include, but are not limited to, fluctuating census numbers, litigation costs and the customer’s participation in programs funded by federal and state governmental agencies. Deviations in the timing or amounts of reimbursements under those programs can impact the customer’s cash flows and its ability to make timely payments. However, the customer’s obligation to pay the Company in accordance with the contract is not contingent upon the customer’s cash flow. Notwithstanding the Company’s efforts to minimize its credit risk exposure, the aforementioned factors, as well as other factors that impact customer cash flows or ability to make timely payments, could have an indirect, yet material, adverse effect on the Company’s results of operations and financial condition. Fluctuations in net accounts and notes receivable are generally attributable to a variety of factors including, but not limited to, the timing of cash receipts from customers and the inception, transition, modification or termination of customer relationships. The Company deploys significant resources and invests in tools and processes to optimize Management’s credit and collections efforts. When appropriate, the Company utilizes interest-bearing promissory notes to enhance the collectability of amounts due, by instituting definitive repayment plans and providing a means by which to further evidence the amounts owed. In addition, the Company may amend contracts from full service to management-only arrangements, or adjust contractual payment terms, to accommodate customers who have in good faith established clearly-defined plans for addressing cash flow issues. These efforts are intended to minimize the Company’s collections risk.

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts	6 Months Ended
Allowance for Doubtful Accounts	Jun. 30, 2024
Receivables [Abstract]
Allowance for Doubtful Accounts	Note 5—Allowance for Doubtful Accounts In making the Company’s credit evaluations, management considers the general collection risk associated with trends in the long-term care industry. The Company establishes credit limits through payment terms with customers, performs ongoing credit evaluations and monitors accounts on an aging schedule basis to minimize the risk of loss. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. As a result, the Company’s future collection experience could differ significantly from historical collection trends. If the Company’s customers experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition. The Company evaluates its accounts and notes receivable for expected credit losses quarterly. Accounts receivable are evaluated based on internally developed credit quality indicators derived from the aging of receivables. Notes receivable are evaluated based on internally developed credit quality indicators derived from management’s assessment of collection risk. At the end of each period, the Company sets a reserve for expected credit losses on standard accounts and notes receivable based on the Company’s historical loss rates. Accounts and notes receivable with an elevated risk profile, which are from customers who have filed bankruptcy or are subject to collections activity, are aggregated and evaluated to determine the total reserve for the class of receivable. Additionally, for notes receivable, management evaluates standard receivables based on whether the customer is current (paying within 60 days of terms) or delinquent (paying outside of 60 days of terms). As of June 30, 2024, the delinquent notes receivable loss pool includes the balance of notes receivable due from Genesis. ASC 326 permits entities to make an accounting policy election not to measure an estimate for credit losses on accrued interest if those entities write-off accrued interest deemed uncollectible in a timely manner. The Company follows an income recognition policy on all interest earned on notes receivable. Under such policy the Company accounts for all notes receivable on a non-accrual basis and defers the recognition of any interest income until receipt of cash payments. This policy was established based on the Company’s history of collections of interest on outstanding notes receivable, as we do not deem it probable that we will receive substantially all interest on outstanding notes receivable. Accordingly, the Company does not record a credit loss adjustment for accrued interest. Interest income from notes receivable for the three months ended June 30, 2024 and 2023 was $0.6 million and $0.7 million, respectively. Interest income from notes receivable for the six months ended June 30, 2024 and 2023 was $1.7 million and $1.3 million, respectively. During June 2024, LaVie Care Centers, LLC (“LaVie"), a customer of the Company, filed for Chapter 11 bankruptcy protection in the Northern District of Georgia. The Company increased the allowance for doubtful accounts by $17.6 million related to outstanding LaVie invoices during the three months ended June 30, 2024. The Company continues to provide services to LaVie post-petition. Revenues that the Company has earned on post-petition services provided to LaVie are recognized upon cash receipt in accordance with ASC 606, as the Company determines that collectability of substantially all of the entitled consideration in exchange for services provided is not probable for customers with ongoing bankruptcy proceedings until such cash is received. The following table presents the Company’s three tiers of notes receivable further disaggregated by year of origination as of June 30, 2024 and write-off activity for the six months ended June 30, 2024. Notes receivable Amortized cost basis by origination year 2024 2023 2022 2021 2020 Prior Total (in thousands) Notes receivable Standard notes receivable $ 7,733 $ 8,515 $ 19,482 $ — $ — $ — $ 35,730 Delinquent notes receivable $ — $ 6,460 $ 2,287 $ 774 $ 1,491 $ 21,336 $ 32,348 Elevated risk notes receivable $ — $ — $ — $ 7,378 $ — $ — $ 7,378 Current-period gross write-offs $ — $ — $ 41 $ — $ — $ 28 $ 69 Current-period recoveries — — — — — — — Current-period net write-offs $ — $ — $ 41 $ — $ — $ 28 $ 69 The following table provides information as to the status of payment on the Company’s notes receivable which were past due as of June 30, 2024. Age analysis of past-due notes receivable as of June 30, 2024 0 - 90 Days 91 - 180 Days Greater than 181 Days Total (in thousands) Notes receivable Standard notes receivable $ 585 $ — $ — $ 585 Delinquent notes receivable $ 1,797 $ 9,759 $ 16,887 $ 28,443 Elevated risk notes receivable $ 569 $ 569 $ 2,087 $ 3,225 $ 2,951 $ 10,328 $ 18,974 $ 32,253 The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the three months ended June 30, 2024 and 2023. Allowance for doubtful accounts Portfolio Segment: March 31, 2024 Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 84,087 $ (11,955) $ 31,561 $ 103,693 Notes receivable Standard notes receivable $ 3,047 $ — $ (60) $ 2,987 Delinquent notes receivable 3,698 (69) 221 3,850 Elevated risk notes receivable 4,755 — — 4,755 Total notes receivable $ 11,500 $ (69) $ 161 $ 11,592 Total accounts and notes receivable $ 95,587 $ (12,024) $ 31,722 $ 115,285 1. Write-offs are shown net of recoveries. During the three months ended June 30, 2024, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. Allowance for doubtful accounts Portfolio segment: March 31, Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 68,407 $ (8,365) $ 10,378 $ 70,420 Notes receivable Standard notes receivable $ 6,425 $ (101) $ 684 $ 7,008 Elevated risk notes receivable 2,035 (2) 201 2,234 Total notes receivable $ 8,460 $ (103) $ 885 $ 9,242 Total accounts and notes receivable $ 76,867 $ (8,468) $ 11,263 $ 79,662 1. Write-offs are shown net of recoveries. During the three months ended June 30, 2023, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the six months ended June 30, 2024 and 2023. Delinquent notes receivable were not considered a separate portfolio segment at December 31, 2023. The amount presented in the table below for the allowance for doubtful accounts for delinquent notes receivable was included within the standard notes receivable portfolio at December 31, 2023. Allowance for doubtful accounts Portfolio Segment: December 31, 2023 1 Write-Offs 2 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 80,819 $ (12,988) $ 35,862 $ 103,693 Notes receivable Standard notes receivable $ 3,510 $ — $ (523) $ 2,987 Delinquent notes receivable 2,615 (69) 1,304 3,850 Elevated risk notes receivable 4,755 — — 4,755 Total notes receivable $ 10,880 $ (69) $ 781 $ 11,592 Total accounts and notes receivable $ 91,699 $ (13,057) $ 36,643 $ 115,285 1. The December 31, 2023 balance includes transfers of $2.6 million from the standard notes receivable portfolio segment to the delinquent notes receivable portfolio segment. 2. Write-offs are shown net of recoveries. During the six months ended June 30, 2024, the Company collected $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. Allowance for doubtful accounts Portfolio segment: December 31, Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 66,601 $ (11,818) $ 15,637 $ 70,420 Notes receivable Standard notes receivable $ 6,052 $ (101) $ 1,057 $ 7,008 Elevated risk notes receivable 811 (53) 1,476 2,234 Total notes receivable $ 6,863 $ (154) $ 2,533 $ 9,242 Total accounts and notes receivable $ 73,464 $ (11,972) $ 18,170 $ 79,662 1. Write-offs are shown net of recoveries. During the six months ended June 30, 2023, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible.

Changes in Accumulated Other Co

Changes in Accumulated Other Comprehensive Loss by Component	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Changes in Accumulated Other Comprehensive Loss by Component	Note 6—Changes in Accumulated Other Comprehensive Loss by Component The Company’s accumulated other comprehensive loss consists of unrealized gains and losses from the Company’s available-for-sale marketable securities and restricted marketable securities. The following table provides a summary of the changes in accumulated other comprehensive loss for the six months ended June 30, 2024 and 2023: Unrealized Gains and Losses on Available-for-Sale Securities¹ Six Months Ended June 30, 2024 2023 (in thousands) Accumulated other comprehensive loss — beginning balance $ (1,844) $ (3,477) Other comprehensive (loss) income before reclassifications (1,040) 344 Income reclassified from other comprehensive loss² 267 3 Net current period other comprehensive (loss) income³ (773) 347 Accumulated other comprehensive loss — ending balance $ (2,617) $ (3,130) 1. All amounts are net of tax. 2. Realized gains and losses were recorded pre-tax within “Investment and other income, net” in the Consolidated Statements of Comprehensive (Loss) Income. For the six months ended June 30, 2024 and 2023, the Company recorded realized losses of $0.3 million and less than $0.1 million, respectively from the sale of available-for-sale securities. Refer to Note 10—Fair Value Measurements herein for further information. 3. For the six months ended June 30, 2024 and 2023, the changes in other comprehensive loss were net of a tax benefit of $0.1 million and an expense of $0.1 million, respectively. The following table provides a rollforward of amounts reclassified from accumulated other comprehensive loss to realized losses for the three and six months ended June 30, 2024 and 2023: Amounts Reclassified from Accumulated Other Comprehensive Loss 2024 2023 (in thousands) Three Months Ended June 30, Losses from the sale of available-for-sale securities $ (126) $ (2) Tax benefit 26 1 Net loss reclassified from accumulated other comprehensive loss $ (100) $ (1) Six Months Ended June 30, Losses from the sale of available-for-sale securities $ (337) $ (4) Tax benefit 70 1 Net losses reclassified from accumulated other comprehensive loss $ (267) $ (3)

Property and Equipment

Property and Equipment	6 Months Ended
Property and Equipment	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7—Property and Equipment Property and equipment are recorded at cost. Depreciation is recorded over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred. The following table sets forth the amounts of property and equipment by each class of depreciable asset as of June 30, 2024 and December 31, 2023: June 30, 2024 December 31, 2023 (in thousands) Housekeeping and dietary equipment $ 17,015 $ 15,764 Computer hardware and software 7,059 6,870 Operating lease — right-of-use assets 28,879 27,099 Other 1 901 1,070 Total property and equipment, at cost 53,854 50,803 Less accumulated depreciation 2 24,014 22,029 Total property and equipment, net $ 29,840 $ 28,774 1. Includes furniture and fixtures, leasehold improvements and autos and trucks. 2. Includes $10.7 million and $9.4 million related to accumulated depreciation on Operating lease – right-of-use assets as of June 30, 2024 and December 31, 2023, respectively. Depreciation expense for the three and six months ended June 30, 2024 was $3.0 million and $5.9 million, respectively. Depreciation expense for the three and six months ended June 30, 2023 was $2.4 million and $4.9 million, respectively. Of the depreciation expense recorded for the three and six months ended June 30, 2024, $1.9 million and $3.8 million, respectively, was related to the depreciation of the Company’s operating lease - right-of-use assets ( “ ROU Assets”). Of the depreciation expense recorded for the three and six months ended June 30, 2023, $1.6 million and $2.8 million, respectively, was related to the depreciation of the Company’s ROU Assets.

Leases

Leases	6 Months Ended
Leases	Jun. 30, 2024
Leases [Abstract]
Leases	Note 8—Leases The Company recognizes ROU assets and lease liabilities for automobiles, office buildings, IT equipment and small storage units for the temporary storage of operational equipment. The Company’s leases have remaining lease terms ranging from less than 1 year to 5 years and have extension options ranging from 1 year to 5 years. Most leases include the option to terminate the lease within 1 year. The Company uses practical expedients offered under ASC 842 to combine lease and non-lease components within leasing arrangements and to recognize the payments associated with short-term leases in earnings on a straight-line basis over the lease term, with the cost associated with variable lease payments recognized when incurred. These accounting policy elections impact the value of the Company’s ROU assets and lease liabilities. The value of the Company’s ROU assets is determined as the non-depreciated fair value of its leasing arrangements and is recorded in “Property and equipment, net” on the Company’s Consolidated Balance Sheets. The value of the Company’s lease liabilities is the present value of fixed lease payments not yet paid, which is discounted using either the rate implicit in the lease contract if that rate can be determined or the Company’s incremental borrowing rate ( “ IBR”) and is recorded in “Other accrued expenses and current liabilities” and “Lease liability — long-term” on the Company’s Consolidated Balance Sheets. The Company’s IBR is determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. Any future lease payments that are not fixed based on the terms of the lease contract, or fluctuate based on a factor other than an index or rate, are considered variable lease payments and are not included in the value of the Company’s ROU assets or lease liabilities. The Company’s variable lease payments are mostly incurred from automobile leases and relate to miscellaneous transportation costs including repair costs, insurance, and terminal rental adjustment payments due at lease settlement. Such rental adjustment payments can result in a reduction to the Company’s total variable lease payments. Components of lease expense required by ASC 842 are presented below for the three and six months ended June 30, 2024 and 2023. Three Months Ended June 30, 2024 2023 (in thousands) Lease cost Operating lease cost $ 1,945 $ 1,444 Short-term lease cost 323 422 Variable lease cost 551 633 Total lease cost $ 2,819 $ 2,499 Six Months Ended June 30, 2024 2023 (in thousands) Lease cost Operating lease cost $ 3,782 $ 2,831 Short-term lease cost 494 654 Variable lease cost 841 1,083 Total lease cost $ 5,117 $ 4,568 Supplemental information required by ASC 842 is presented below for the six months ended June 30, 2024 and 2023. Six Months Ended June 30, 2024 2023 (dollar amounts in thousands) Other information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 3,958 $ 3,110 Weighted-average remaining lease term — operating leases 2.9 years 3.7 years Weighted-average discount rate — operating leases 6.9 % 6.0 % During the three and six months ended June 30, 2024, the Company’s ROU assets and lease liabilities were reduced by $0.3 million and $0.5 million, respectively, due to lease cancellations. During the three and six months ended June 30, 2023, the Company's ROU assets and lease liabilities were reduced by $0.4 million and $1.1 million, respectively, due to lease cancellations. The following is a schedule by calendar year of future minimum lease payments under operating leases that have remaining terms as of June 30, 2024: Period/Year Operating Leases (in thousands) July 1 to December 31, 2024 $ 4,058 2025 7,964 2026 5,201 2027 1,797 2028 1,389 2029 116 Thereafter — Total minimum lease payments $ 20,525 Less: imputed interest 1,917 Present value of lease liabilities $ 18,608

Other Intangible Assets

Other Intangible Assets	6 Months Ended
Other Intangible Assets	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets	Note 9—Other Intangible Assets The Company’s other intangible assets consist of customer relationships, trade names, patents and non-compete agreements which were obtained through acquisitions and are recorded at their fair values at the date of acquisition. Intangible assets with determinable lives are amortized on a straight-line basis over their estimated useful lives. The weighted-average amortization period of customer relationships, trade names, patents and non-compete agreements are approximately 10 years, 13 years, 8 years and 4 years, respectively. The following table sets forth the estimated amortization expense for intangibles subject to amortization for the remainder of 2024, the following five fiscal years and thereafter: Period/Year Total Amortization Expense (in thousands) July 1 to December 31, 2024 $ 1,343 2025 $ 2,685 2026 $ 2,666 2027 $ 1,196 2028 $ 613 2029 $ 508 Thereafter $ 1,774 Amortization expense for the three months ended June 30, 2024 and 2023 was $0.7 million and $1.2 million, respectively. Amortization expense for the six months ended June 30, 2024 and 2023 was $1.3 million and $2.4 million, respectively.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10—Fair Value Measurements The Company’s current assets and current liabilities are financial instruments and most of these items (other than marketable securities, restricted marketable securities, inventories and the short-term portion of deferred compensation funding) are recorded at cost in the Consolidated Balance Sheets. The estimated fair value of these financial instruments approximates their carrying value due to their short-term nature. The carrying value of the Company’s line of credit represents the outstanding amount of the borrowings, which approximates fair value. The Company’s financial assets that are measured at fair value on a recurring basis are its marketable securities, restricted marketable securities, and deferred compensation funding. The recorded values of all of the financial instruments approximate their current fair values because of their nature, stated interest rates and respective maturity dates or durations. The Company’s marketable securities are held by the Company’s captive insurance company to satisfy capital requirements of the state regulator related to captive insurance companies. Restricted marketable securities are held by the Company’s captive insurance company as collateral for certain insurance coverages. Such securities consist primarily of municipal bonds, U.S. treasury bonds and corporate bonds, which are classified as available-for-sale and are reported at fair value. Unrealized gains and losses associated with these investments are included within “Unrealized (loss) gain on available-for-sale marketable securities, net of taxes” in the Consolidated Statements of Comprehensive (Loss) Income. Marketable securities, including restricted marketable securities, are classified within Level 2 of the fair value hierarchy, as these securities are measured using quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable. Such valuations are determined by a third-party pricing service. For the three and six months ended June 30, 2024, the Company recorded unrealized losses, net of taxes of $0.4 million and $0.8 million on marketable securities and restricted marketable securities, respectively. For the three and six months ended June 30, 2023, the Company recorded unrealized losses, net of taxes of $0.9 million and unrealized gains, net of taxes of $0.3 million on marketable securities, respectively. As part of a 2021 acquisition of a prepackaged meal manufacturer, the Company agreed to pay royalties to the seller on all future product sales. The Company recorded a liability for the expected future payments within Other long-term liabilities in the Consolidated Balance Sheets. The fair value of this liability is measured using forecasted sales models (Level 3). For the three months ended June 30, 2024 and 2023, the Company recorded realized losses of $0.5 million and gains of $0.6 million, respectively, within “Costs of services provided” in the Consolidated Statements of Comprehensive (Loss) Income related to the subsequent measurement of the liability at each balance sheet date. For the six months ended June 30, 2024 and 2023, the Company recorded realized gains of $0.3 million and $0.2 million, respectively, within “Costs of services provided” in the Consolidated Statements of Comprehensive (Loss) Income related to the subsequent measurement of the liability at each period end. For the three months ended June 30, 2024 and 2023, the Company received total proceeds, less the amount of interest received, of $11.4 million and $1.2 million, respectively, from sales of available-for-sale securities. For the three months ended June 30, 2024 and 2023, these sales resulted in realized losses of $0.1 million and gains of less than $0.1 million, respectively, which were recorded within “Investment and other income, net” in the Consolidated Statements of Comprehensive (Loss) Income. For the six months ended June 30, 2024 and 2023, the Company received total proceeds, less the amount of interest received, of $28.0 million and $1.4 million, respectively, from sales of available-for-sale securities. For the six months ended June 30, 2024 and 2023, these sales resulted in realized losses of $0.3 million and losses of less than $0.1 million, respectively, which were recorded within “Investment and other income, net” in the Consolidated Statements of Comprehensive (Loss) Income. The basis for the sale of these securities was the specific identification of each bond sold during the period. The investments under the funded deferred compensation plan are classified as trading securities and unrealized gains or losses are recorded within “Investment and other income, net” in the Consolidated Statements of Comprehensive (Loss) Income . The fair value of the investments are determined based on quoted market prices (Level 1) or the net asset value (“NAV”) of underlying share investments (Level 2). For the three months ended June 30, 2024 and 2023, the Company recognized unrealized gains of $1.3 million and gains of $2.3 million , respectively, related to equity securities held at the respective reporting dates. For the six months ended June 30, 2024 and 2023, the Company recognized unrealized gains of $5.4 million and $3.8 million , respectively, related to equity securities held at the respective reporting dates. The following table summarizes the contractual maturities of debt securities held at June 30, 2024 and December 31, 2023, which are classified as “Marketable securities, at fair value” and “Restricted marketable securities, at fair value” in the Consolidated Balance Sheets: Debt Securities — Available-for-Sale Contractual maturity: June 30, 2024 December 31, 2023 (in thousands) Marketable securities, at fair value Maturing in one year or less $ 1,007 $ 6,324 Maturing in second year through fifth year 27,296 34,939 Maturing in sixth year through tenth year 32,934 39,309 Maturing after ten years 17,897 12,559 Total marketable securities, at fair value $ 79,134 $ 93,131 Restricted marketable securities, at fair value Maturing in one year or less $ 1,047 $ — Maturing in second year through fifth year 7,058 — Maturing in sixth year through tenth year 12,895 — Maturing after ten years 1,022 — Total restricted marketable securities, at fair value $ 22,022 $ — Total debt securities — available-for-sale $ 101,156 $ 93,131 The following table shows the amortized cost, unrealized gains and losses, and estimated fair value of the Company’s debt securities as of June 30, 2024 and December 31, 2023: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Credit Impairment Losses 1 (in thousands) June 30, 2024 Type of security: Marketable securities Municipal bonds — taxable $ 9,242 $ 18 $ (752) $ 8,508 $ — Municipal bonds — non-taxable 73,216 49 (2,639) 70,626 — Total marketable securities $ 82,458 $ 67 $ (3,391) $ 79,134 $ — Restricted marketable securities U.S. treasury bonds $ 6,888 $ 13 $ — $ 6,901 $ — U.S. government agency bonds 1,207 2 — 1,209 — International fixed income bonds 625 — (1) 624 — Corporate bonds 5,134 5 (2) 5,137 — Municipal bonds — taxable 8,156 16 (21) 8,151 — Total restricted marketable securities $ 22,010 $ 36 $ (24) $ 22,022 $ — Total debt securities — available-for-sale $ 104,468 $ 103 $ (3,415) $ 101,156 $ — December 31, 2023 Type of security: Municipal bonds — non-taxable $ 95,466 $ 387 $ (2,722) $ 93,131 $ — Total debt securities — available-for-sale $ 95,466 $ 387 $ (2,722) $ 93,131 $ — 1. The Company performs a credit impairment loss assessment quarterly on an individual security basis. As of June 30, 2024 and December 31, 2023, no allowance for credit loss has been recognized as the issuers of these securities have not established a cause for default and various rating agencies have reaffirmed each security’s investment grade status. The fair value of these securities have fluctuated since the purchase date as market interest rates fluctuate. The Company does not intend to sell these securities and it is more likely than not that the Company will not be required to sell before the recovery of the securities’ amortized cost basis. The following tables provide fair value measurement information for the Company’s financial assets, including marketable securities, restricted marketable securities and deferred compensation fund investments as of June 30, 2024 and December 31, 2023: As of June 30, 2024 Fair Value Measurement Using: Carrying Amount Total Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in thousands) Marketable securities Municipal bonds — taxable $ 8,508 $ 8,508 $ — $ 8,508 $ — Municipal bonds — non-taxable 70,626 70,626 — 70,626 — Total marketable securities $ 79,134 $ 79,134 $ — $ 79,134 $ — Restricted marketable securities U.S. treasury bonds $ 6,901 $ 6,901 $ — $ 6,901 $ — U.S. government agency bonds 1,209 1,209 — 1,209 — International fixed income bonds 624 624 — 624 — Corporate bonds 5,137 5,137 — 5,137 — Municipal bonds — taxable 8,151 8,151 — 8,151 — Total restricted marketable securities $ 22,022 $ 22,022 $ — $ 22,022 $ — Deferred compensation fund Money market 1 $ 1,933 $ 1,933 $ — $ 1,933 $ — Commodities 315 315 315 — — Fixed income 4,605 4,605 4,605 — — International 4,942 4,942 4,942 — — Large cap blend 5,794 5,794 5,794 — — Large cap growth 16,890 16,890 16,890 — — Large cap value 6,543 6,543 6,543 — — Mid cap blend 3,382 3,382 3,382 — — Real estate 350 350 350 — — Small cap blend 2,679 2,679 2,679 — — Total deferred compensation fund 2 $ 47,433 $ 47,433 $ 45,500 $ 1,933 $ — As of December 31, 2023 Fair Value Measurement Using: Carrying Total Fair Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in thousands) Marketable securities Municipal bonds — non-taxable $ 93,131 $ 93,131 $ — $ 93,131 $ — Deferred compensation fund Money market 1 $ 2,007 $ 2,007 $ — $ 2,007 $ — Commodities 298 298 298 — — Fixed income 4,254 4,254 4,254 — — International 4,621 4,621 4,621 — — Large cap blend 5,053 5,053 5,053 — — Large cap growth 13,886 13,886 13,886 — — Large cap value 5,964 5,964 5,964 — — Mid cap blend 3,192 3,192 3,192 — — Real estate 374 374 374 — — Small cap blend 2,664 2,664 2,664 — — Deferred compensation fund 2 $ 42,313 $ 42,313 $ 40,306 $ 2,007 $ — 1. The fair value of the money market fund is based on the NAV of the shares held by the plan at the end of the period. The money market fund includes short-term United States dollar denominated money market instruments and the NAV is determined by the custodian of the fund. The money market fund can be redeemed at its NAV at the measurement date as there are no significant restrictions on the ability to sell this investment. 2. As of June 30, 2024 and December 31, 2023, $1.4 million and $1.5 million of short-term deferred compensation funding is included within “Prepaid expenses and other assets” in the Company’s Consolidated Balance Sheets, respectively. Such amounts of short-term deferred compensation funding represent investments expected to be liquidated and paid within 12 months of June 30, 2024 and December 31, 2023, respectively.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
Share-Based Compensation	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Note 11—Share-Based Compensation The components of the Company’s share-based compensation expense for the six months ended June 30, 2024 and 2023 are as follows: Six Months Ended June 30, 2024 2023 (in thousands) Stock options $ 353 $ 463 Restricted stock, restricted stock units and deferred stock units 3,501 3,223 Performance stock units 665 565 Employee Stock Purchase Plan 78 158 Total pre-tax share-based compensation expense charged against income $ 4,597 $ 4,409 The following table summarizes the components of share-based compensation expense included within the Consolidated Statements of Comprehensive (Loss) Income for the six months ended June 30, 2024 and 2023: Six Months Ended June 30, 2024 2023 (in thousands) Selling, general and administrative expense $ 4,572 $ 4,363 Costs of services provided 25 46 Total share-based compensation expense $ 4,597 $ 4,409 At June 30, 2024, the unrecognized compensation cost related to unvested stock options and awards was $21.2 million. The weighted average period over which these awards will vest is approximately 3.3 years. Amended 2020 Omnibus Incentive Plan On May 26, 2020, the Company adopted the 2020 Omnibus Incentive Plan after approval by the Company’s Shareholders at the 2020 Annual Meeting of Shareholders. On May 30, 2023, the Company increased the authorized shares under the 2020 Omnibus Incentive Plan (as amended, the “Amended 2020 Plan”) by 2.5 million shares after approval by the Company’s Shareholders at the 2023 Annual Meeting of Shareholders. The Amended 2020 Plan provides that current or prospective officers, employees, non-employee directors and advisors can receive share-based awards such as stock options, performance stock units, restricted stock units and other stock awards. The Amended 2020 Plan seeks to encourage profitability and growth of the Company through short-term and long-term incentives that are consistent with the Company’s operating objectives. As of June 30, 2024, there were 6.7 million shares of common stock reserved for issuance under the Amended 2020 Plan, of which 2.3 million are available for future grant. The amount of shares available for issuance under the Amended 2020 Plan will increase when outstanding awards under the Company’s Second Amended and Restated 2012 Equity Incentive Plan (the “2012 Plan”) are subsequently forfeited, terminated, lapsed or satisfied thereunder in cash or property other than shares. No stock award will have a term in excess of 10 years. The Nominating, Compensation and Stock Option Committee of the Board of Directors is responsible for determining the terms of the grants in accordance with the Amended 2020 Plan. Stock Options A summary of stock options outstanding under the Amended 2020 Plan and the 2012 Plan as of December 31, 2023 and changes during the six months ended June 30, 2024 are as follows: Stock Options Outstanding Number of Shares Weighted Average Exercise Price (in thousands) December 31, 2023 2,438 $ 30.43 Granted 290 $ 10.36 Exercised — $ — Forfeited (1) $ 24.43 Expired (179) $ 28.45 June 30, 2024 2,548 $ 28.29 The weighted average grant date fair value of stock options granted during the six months ended June 30, 2024 and 2023 was $5.06 and $6.53 per common share, respectively. No stock options were exercised during the six months ended June 30, 2024 and 2023. The fair value of stock option awards granted during the six months ended June 30, 2024 and 2023 was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions: Six Months Ended June 30, 2024 2023 Risk-free interest rate 3.9 % 4.0 % Weighted average expected life 7.0 years 6.9 years Expected volatility 40.5 % 39.5 % Dividend yield — % — % The following table summarizes other information about the stock options at June 30, 2024: June 30, 2024 (amounts in thousands, except per share data) Outstanding: Aggregate intrinsic value $ 64 Weighted average remaining contractual life 4.9 years Exercisable: Number of options 1,756 Weighted average exercise price $ 33.93 Aggregate intrinsic value $ — Weighted average remaining contractual life 3.4 years Restricted Stock Units The fair value of outstanding restricted stock units was determined based on the market price of the shares on the date of grant. During the six months ended June 30, 2024, the Company granted 0.8 million restricted stock units to its employees with a weighted average grant date fair value of $10.38 per unit. During the six months ended June 30, 2023, the Company granted 0.5 million restricted stock units to its employees with a weighted average grant date fair value of $13.74 per unit. A summary of the outstanding restricted stock units as of December 31, 2023 and changes during the six months ended June 30, 2024 is as follows: Restricted Stock Units Number Weighted Average Grant Date Fair Value (in thousands) December 31, 2023 1,102 $ 18.57 Granted 770 $ 10.38 Vested (297) $ 21.68 Forfeited (17) $ 14.17 June 30, 2024 1,558 $ 13.97 Performance Stock Units On January 3, 2024, the Company issued 0.1 million Performance Stock Units (“PSUs”) to the Company’s executive officers. Such PSUs are contingent upon the achievement of certain total shareholder return (“TSR”) targets as compared to the TSR of the S&P 400 MidCap Index and the participant’s continued employment with the Company for the three year period ending December 31, 2026, the date at which such PSUs vest. The unrecognized share-based compensation cost of the TSR-based PSU awards at June 30, 2024 is $2.1 million and is expected to be recognized over a weighted-average period of 1.9 years. A summary of the outstanding PSUs as of December 31, 2023 and changes during the six months ended June 30, 2024 is as follows: Performance Stock Units Number Weighted Average Grant Date Fair Value (in thousands) December 31, 2023 175 $ 21.52 Granted 118 $ 11.85 Vested — $ — Forfeited (35) $ 34.52 June 30, 2024 258 $ 15.31 Deferred Stock Units The Company grants Deferred Stock Units (“DSUs”) to our non-employee directors. Once vested, the recipient shall be entitled to receive a lump sum payment of a number of shares equal to the total number of DSUs issued to such recipient upon the first to occur of (i) the five year anniversary of the date of grant, (ii) the recipient ’ s death, disability or separation of service from the Board, or (iii) a change of control (as defined by the 2020 Plan). Non-employee directors can also elect to receive their Board of Directors retainer in the form of DSUs in lieu of cash. The number of DSUs granted to these directors is determined based on the stock price on the award date and approximates the cash value the directors would otherwise receive for their retainer. Three non-employee directors made an election in 2023 to receive DSUs in lieu of cash for their 2024 Board of Directors retainer. The unrecognized share-based compensation cost of outstanding DSU awards at June 30, 2024 is $0.3 million and is expected to be recognized over a weighted-average period of 0.9 years. Employee Stock Purchase Plan The Company’s Employee Stock Purchase Plan (“ESPP”) is currently available through 2026 to all eligible employees. All full-time and part-time employees who work an average of 20 hours per week and have completed two years of continuous service with the Company are eligible to participate. Annual offerings commence and terminate on the respective year’s first and last calendar day. Under the ESPP, the Company is authorized to issue up to 4.1 million shares of its common stock to its employees. Pursuant to such authorization, there were 1.8 million shares available for future grant at June 30, 2024. The expense associated with the options granted under the ESPP during the six months ended June 30, 2024 and 2023 was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions: Six Months Ended June 30, 2024 2023 Risk-free interest rate 4.8% 4.8% Weighted average expected life (years) 1.0 1.0 Expected volatility 37.1% 42.9% Dividend yield —% 7.1% Deferred Compensation Plan The Company offers a Supplemental Executive Retirement Plan (“SERP”) for executives and certain key employees. The SERP allows participants to defer a portion of their earned income on a pre-tax basis and as of the last day of each plan year, each participant will be credited with a match of a portion of their deferral in the form of the Company’s common stock based on the then-current market value. Under the SERP, the Company is authorized to issue 1.0 million shares of its common stock to its employees. Pursuant to such authorization, the Company has 0.2 million shares available for future grant at June 30, 2024. At the time of issuance, such shares are accounted for at cost as treasury stock. The following table summarizes information about the SERP during the six months ended June 30, 2024 and 2023: Six Months Ended June 30, 2024 2023 (in thousands) SERP expense 1 $ 355 $ 298 Unrealized gain recorded in SERP liability account $ 5,350 $ 3,871 1. Both the SERP match and the deferrals are included in the “ Selling, general and administrative expense ”

Income Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 12—Income Taxes The Company’s annual effective tax rate is impacted by the tax effects of option exercises and the vesting of awards, which are treated as discrete items in the reporting period in which they occur and therefore cannot be considered in the calculation of the estimated annual effective tax rate. Discrete items increased the Company’s income tax provision recognized through the six months ended June 30, 2024 and 2023 by $1.2 million and $1.1 million, respectively. Differences between the effective tax rate and the applicable U.S. federal statutory rate arise primarily from the effect of state and local income taxes, share-based compensation and tax credits available to the Company. The actual 2024 effective tax rate will likely vary from the estimate depending on the actual operating income earned with availability of tax credits, the exercising of stock options and vesting of share-based awards. The Company regularly evaluates the tax positions taken or expected to be taken resulting from financial statement recognition of certain items. Based on the evaluation, there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The evaluation was performed for the tax years ended December 31, 2019 through 2023 (with regard to U.S. federal income tax returns) and December 31, 2018 through 2023 (with regard to various state and local income tax returns), the tax years which remain subject to examination by major tax jurisdictions as of June 30, 2024.

Segment Information

Segment Information	6 Months Ended
Segment Information	Jun. 30, 2024
Segment Reporting [Abstract]
Segment Information	Note 13—Segment Information The Company manages and evaluates its operations in two reportable segments: Housekeeping (housekeeping, laundry, linen and other services) and Dietary (dietary department services). Although both segments serve a similar customer base and share many operational similarities, they are managed separately due to distinct differences in the type of services provided, as well as the specialized expertise required of the professional management personnel responsible for delivering each segment’s services. Such services are rendered pursuant to discrete contracts, specific to each reportable segment. The Company’s accounting policies for the segments are generally the same as described in the Company’s significant accounting policies. Differences between the reportable segments’ operating results and other disclosed data and the information in the consolidated financial statements relate primarily to corporate-level transactions and recording of transactions at the reportable segment level using other than generally accepted accounting principles. There are certain inventories and supplies that are primarily expensed when incurred within the operating segments which are capitalized in the consolidated financial statements. In addition, most corporate expenses such as corporate salary and benefit costs, certain legal costs, debt expense, information technology costs, depreciation, amortization of finite-lived intangible assets, share-based compensation costs and other corporate-specific costs, are not fully allocated to the operating segments. There are also allocations for workers’ compensation and general liability expense within the operating segments that differ from the actual expense recorded by the Company under U.S. GAAP. Segment amounts disclosed are prior to elimination entries made in consolidation. Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (in thousands) Revenues Housekeeping $ 191,006 $ 190,817 $ 381,565 $ 384,336 Dietary 235,282 228,114 468,156 451,825 Total $ 426,288 $ 418,931 $ 849,721 $ 836,161 Income before income taxes Housekeeping $ 17,017 $ 16,608 $ 35,459 $ 36,661 Dietary 14,932 12,443 32,559 27,110 Corporate and eliminations 1 (33,935) (18,117) (48,690) (36,682) Total $ (1,986) $ 10,934 $ 19,328 $ 27,089 1. Primarily represents corporate office costs and related overhead, recording of certain inventories and supplies and workers’ compensation costs at the reportable segment level which use accounting methods that differ from those used at the corporate level, as well as consolidated subsidiaries’ operating expenses that are not allocated to the reportable segments, net of investment and other income and interest expense.

Basic (Loss) Earnings Per Commo

Basic (Loss) Earnings Per Common Share	6 Months Ended
Basic (Loss) Earnings Per Common Share	Jun. 30, 2024
Earnings Per Share [Abstract]
Basic (Loss) Earnings Per Common Share	Note 14—Basic (Loss) Earnings Per Common Share Basic and diluted (loss) earnings per common share are computed by dividing net (loss) income by the weighted-average number of basic and diluted common shares outstanding, respectively. The weighted-average number of diluted common shares includes the impact of dilutive securities, including outstanding stock options, restricted stock units, performance stock units and deferred stock units. The table below reconciles the weighted-average basic and diluted common shares outstanding: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (in thousands, except for per share amounts) Numerator for basic and diluted (loss) earnings per share: Net (loss) income $ (1,788) $ 8,254 $ 13,521 $ 19,925 Denominator Weighted average number of common shares outstanding - basic 73,853 74,478 73,889 74,488 Effect of dilutive securities 1 — 89 159 55 Weighted average number of common shares outstanding - diluted 73,853 74,567 74,048 74,543 Basic (loss) earnings per share: $ (0.02) $ 0.11 $ 0.18 $ 0.27 Diluted (loss) earnings per share: $ (0.02) $ 0.11 $ 0.18 $ 0.27 1. Certain outstanding equity awards are anti-dilutive and therefore excluded from the calculation of the weighted average number of diluted common shares outstanding. Anti-dilutive outstanding equity awards under share-based compensation plans were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (in thousands) Anti-dilutive 3,000 3,077 2,844 2,721

Other Contingencies

Other Contingencies	6 Months Ended
Other Contingencies	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Other Contingencies	Note 15—Other Contingencies Line of Credit At June 30, 2024, the Company had a $300.0 million bank line of credit on which to draw for general corporate purposes. Amounts drawn under the line of credit are payable upon demand and generally bear interest at a floating rate, based on the Company’s leverage ratio, and starting at the Term Secured Overnight Financing Rate (“SOFR”) plus 165 basis points. As of June 30, 2024, there were $30.0 million in borrowings under the line of credit. As of December 31, 2023, there were $25.0 million in borrowings under the line of credit. The line of credit requires the Company to satisfy two financial covenants, with which the Company is in compliance as of June 30, 2024. The line of credit expires on November 22, 2027. At June 30, 2024, the Company also had outstanding $60.2 million in irrevocable standby letters of credit, which relate to payment obligations under the Company’s insurance programs. In connection with the issuance of the letters of credit, the amount available under the line of credit was reduced by $60.2 million to $209.8 million at June 30, 2024. The letters of credit expire during the first quarter of 2025. Tax Jurisdictions and Matters The Company provides services throughout the continental United States and is subject to numerous state and local taxing jurisdictions. In the ordinary course of business, a jurisdiction may contest the Company’s reporting positions with respect to the application of its tax code to the Company’s services, which could result in additional tax liabilities. The Company has tax matters with various taxing authorities. Because of the uncertainties related to both the probable outcomes and amount of probable assessments due, the Company is unable to make a reasonable estimate of a liability. The Company does not expect the resolution of any of these matters, taken individually or in the aggregate, to have a material adverse effect on the consolidated financial position or results of operations based on the Company’s best estimate of the outcomes of such matters. Legal Proceedings The Company is subject to various claims and legal actions in the ordinary course of business. Some of these matters include payroll- and employee-related matters and examinations by governmental agencies. As the Company becomes aware of such claims and legal actions, the Company records accruals for any exposures that are probable and estimable. If adverse outcomes of such claims and legal actions are reasonably possible, Management assesses materiality and provides financial disclosure, as appropriate. At this time, the Company is unable to reasonably estimate possible losses or form a judgment that an unfavorable outcome is either probable or remote with respect to certain pending litigation claims asserted and it is not currently possible to assess whether or not the outcome of these proceedings may have a material adverse effect on the Company. Government Regulations

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 16—Subsequent Events The Company evaluated all subsequent events through the filing date of this Form 10-Q. There were no events or transactions occurring during this subsequent reporting period which require recognition or additional disclosure in these financial statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net (loss) income	$ (1,788)	$ 15,309	$ 8,254	$ 11,671	$ 13,521	$ 19,925

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business and S_2

Description of Business and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Nature of Operations	Healthcare Services Group, Inc. (the “Company”) provides management, administrative and operating expertise and services to the housekeeping, laundry, linen, facility maintenance and dietary service departments predominantly to clients within the healthcare industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals located throughout the United States. Although the Company does not directly participate in any government reimbursement programs, the Company’s customers receive government reimbursements related to Medicare and Medicaid. Therefore, the Company’s customers are directly affected by any legislation relating to Medicare and Medicaid reimbursement programs. The Company provides services primarily pursuant to full service agreements with its customers. In such agreements, the Company is responsible for the day-to-day management of its employees located at the customers’ facilities, as well as for the provision of certain supplies. The Company also provides services on the basis of management-only agreements for a limited number of customers. In a management-only agreement, the Company provides management and supervisory services while the customer facility retains payroll responsibility for the non-supervisory staff. The agreements with customers typically provide for a renewable one year service term, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days. The Company is organized into two reportable segments: housekeeping, laundry, linen and other services (“Housekeeping”), and dietary department services (“Dietary”). Housekeeping consists of managing the customers’ housekeeping departments, which are principally responsible for the cleaning, disinfecting and sanitizing of resident rooms and common areas of a customer’s facility, as well as the laundering and processing of the bed linens, uniforms, resident personal clothing and other assorted linen items utilized at a customer facility. Dietary consists of managing the customers’ dietary departments, which are principally responsible for food purchasing, meal preparation and dietitian professional services, which includes the development of menus that meet residents’ dietary needs.
Unaudited Interim Financial Data	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and the requirements of Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations and cash flows. However, in the Company’s opinion, all adjustments which are of a normal recurring nature and are necessary for a fair presentation have been reflected in these consolidated financial statements. The balance sheet shown in this report as of December 31, 2023 has been derived from the audited financial statements for the year ended December 31, 2023. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for any future period.
Use of Estimates in Financial Statements	In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes.
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of Healthcare Services Group, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Cash and Cash Equivalents	Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as short-term, highly liquid investments with a maturity of three months or less at time of purchase that are readily convertible into cash and have insignificant interest rate risk.
Restricted Cash Equivalents	Restricted cash equivalents represent highly liquid investments held in a trust account as collateral for certain insurance coverages the Company obtained from a third-party insurance carrier.
Accounts and Notes Receivable	Accounts and notes receivable consist of Housekeeping and Dietary segment trade receivables from contracts with customers. The Company’s payment terms with customers for services provided are defined within each customer’s service agreement. Accounts receivable are considered short term assets as the Company does not grant payment terms greater than one year. Accounts receivable initially are recorded at the transaction amount and are recorded after the Company has an unconditional right to payment where only the passage of time is required before payment is received. Each reporting period, the Company evaluates the collectability of outstanding receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit loss. Additions to the allowance for doubtful accounts are made by recording a charge to bad debt expense reported in costs of services provided. Notes receivable are initially recorded when accounts receivable are transferred into a promissory note and are recorded as an alternative to accounts receivable to memorialize an unqualified promise to pay a specific sum, typically with interest, in accordance with a defined payment schedule. The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however most promissory notes mature over 1 to 4 years. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses.
Allowance for Doubtful Accounts	Management utilizes financial modeling to determine an allowance that reflects its best estimate of the lifetime expected credit losses on accounts and notes receivable which is recorded to offset the receivables. Modeling is prepared after considering historical experience, current conditions and reasonable and supportable economic forecasts to estimate lifetime expected credit losses. Accounts and notes receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded as a reduction of bad debt expense when received.
Inventories and Supplies	Inventories and supplies include housekeeping, linen and laundry supplies, as well as food provisions and supplies. Non-linen inventories and supplies are stated on a first-in, first-out (“FIFO”) basis, and reduced as deemed necessary to approximate the lower of cost or net realizable value. Linen supplies are amortized on a straight-line basis over their estimated useful life of 24 months.
Revenue Recognition	The Company recognizes revenue from contracts with customers when or as the promised goods and services are provided to customers. Revenues are reported net of sales taxes that are collected from customers and remitted to taxing authorities. The amount of revenue recognized by the Company is based on the expected value of consideration to which the Company is entitled in exchange for providing the contracted goods and services and when it is probable that the Company will collect substantially all of such consideration.
Leases	The Company records assets and liabilities on the Consolidated Balance Sheets to recognize the rights and obligations arising from leasing arrangements with contractual terms greater than 12 months. A leasing arrangement includes any contract which entitles the Company to the right of use of an identified tangible asset where there are no restrictions as to the direction of use of the asset and the Company obtains substantially all of the economic benefits from the right of use.
Income Taxes	The Company uses the asset and liability method of accounting for income taxes. Under this method, income tax expense or benefits are recognized for the amount of taxes payable or refundable for the current period. The Company accrues for probable tax obligations as required based on facts and circumstances in various regulatory environments. In addition, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. When appropriate, valuation allowances are recorded to reduce deferred tax assets to amounts for which realization is more likely than not.
(Loss) Earnings per Common Share	Basic (loss) earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted (loss) earnings per common share is computed using the weighted-average number of common shares outstanding and dilutive common shares, such as those issuable upon exercise of stock awards. Diluted loss per common share excludes dilutive potential common shares from the calculation, as their inclusion would be anti-dilutive.
Share-Based Compensation	The Company estimates the fair value of share-based awards on the date of grant using a Black-Scholes valuation model for stock options, using a Monte Carlo simulation for performance restricted stock units, and using the share price on the date of grant for restricted stock units and deferred stock units. The value of the award is recognized ratably as an expense in the Company’s Consolidated Statements of Comprehensive (Loss) Income over the requisite service periods with adjustments made for forfeitures as they occur.
Goodwill and Other Intangible Assets	Goodwill represents the excess of cost over the fair value of net assets of acquired businesses. Management reviews the carrying value of goodwill annually during the fourth quarter to assess for impairment or more often if events or circumstances indicate that the carrying value may exceed its estimated fair value. Other intangible assets are amortized on a straight-line basis over their respective useful lives.
Investments in Equity Securities	The Company accounts for investments in equity securities using the equity method when the Company determines that it can exercise significant influence over the investee. The Company accounts for investments in equity securities at fair value when the Company determines that it cannot exercise significant influence over the investee. During the six months ended June 30, 2024, the Company invested $2.8 million for a 25% ownership share in a health care technology company which specializes in the long-term and acute care markets which was accounted for as an equity method investment. Investments in equity securities are recorded within “Other long-term assets” in the Company’s Consolidated Balance Sheets. The Company’s proportionate share of earnings or losses of the investee are recorded within “Investment and other income, net” on the Company's Consolidated Statements of Comprehensive (Loss) Income. The Company elects to record its proportionate share of earnings or losses in equity method investments using a three-month lag based on the most recently available financial statements.
Concentrations of Credit Risk	The Company’s financial instruments that are subject to credit risk are cash and cash equivalents, restricted cash equivalents, marketable securities, restricted marketable securities, deferred compensation funding and accounts and notes receivable. At June 30, 2024, the majority of the Company’s cash and cash equivalents, restricted cash equivalents, marketable securities and restricted marketable securities were held in two large financial institutions located in the United States. At December 31, 2023, the majority were held in one large financial institution located in the United States. The Company’s marketable securities and restricted marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. The Company’s deferred compensation funding consists of fund and money market investments all of which are highly liquid and held in a trust account. The Company’s customers are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s customers are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the Company’s customers participate. As a result, the Company may not realize the full effects such programs may have on the Company’s customers until such new legislation or changes in existing regulations are fully implemented and governmental agencies issue applicable regulations or guidance.
Employee Retention Credit	On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). One provision within the CARES Act provided an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable tax credit against the employer share of Social Security tax equal to 50% of the qualified wages paid to employees from March 13, 2020 through December 31, 2020. The ERC was subsequently expanded in 2021 for employers to claim a refundable tax credit for 70% of the qualified wages paid to employees from January 1, 2021 through September 30, 2021. The Company accounted for the ERC by analogy to International Accounting Standard (“IAS”) 20, Accounting for Government Grants and Disclosure of Government Assistance. During the quarter ended June 30, 2023, the Company filed a claim for the ERC for qualified wages paid in 2020 and 2021 and through July 26, 2024 has yet to receive any refunds or receive any correspondence from the IRS regarding the ERC filing. The Company believes that there is not reasonable assurance that any receipt of credits will be obtained and therefore has not recognized any amounts related to the ERC in the accompanying consolidated financial statements. Should reasonable assurance over receipt of and compliance with terms of the ERC credits be obtained in future periods, the Company would recognize such amounts as an offset to expense within “Costs of services provided” on the Consolidated Statements of Comprehensive (Loss) Income. In the event the Company obtains a refund in future periods, such refunds would be subject to IRS audit under the applicable statute of limitations.
Reclassifications	Prior period line items in the Consolidated Statements of Stockholders’ Equity have been revised to conform with current period presentation.
Segment Information	The Company’s accounting policies for the segments are generally the same as described in the Company’s significant accounting policies. Differences between the reportable segments’ operating results and other disclosed data and the information in the consolidated financial statements relate primarily to corporate-level transactions and recording of transactions at the reportable segment level using other than generally accepted accounting principles. There are certain inventories and supplies that are primarily expensed when incurred within the operating segments which are capitalized in the consolidated financial statements. In addition, most corporate expenses such as corporate salary and benefit costs, certain legal costs, debt expense, information technology costs, depreciation, amortization of finite-lived intangible assets, share-based compensation costs and other corporate-specific costs, are not fully allocated to the operating segments. There are also allocations for workers’ compensation and general liability expense within the operating segments that differ from the actual expense recorded by the Company under U.S. GAAP. Segment amounts disclosed are prior to elimination entries made in consolidation.

Description of Business and S_3

Description of Business and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets to the amount reported in the Consolidated Statements of Cash Flows. June 30, 2024 June 30, 2023 (in thousands) Cash and cash equivalents $ 26,430 $ 28,662 Restricted cash equivalents 1 3,117 — Total cash and cash equivalents and restricted cash equivalents $ 29,547 $ 28,662 1. On February 2, 2024, the Company entered into a Collateral Trust Agreement with the Company’s third-party insurer and a trustee whereby investments or money market funds are held in a trust account to benefit the insurer and are restricted for that purpose. Restricted cash equivalents represent funds invested in money market accounts as of June 30, 2024. The trust account was set up in conjunction with a reduction in the Company’s letter of credit collateral obligation for insurance obligations.
Schedule of Restricted Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash equivalents reported within the Consolidated Balance Sheets to the amount reported in the Consolidated Statements of Cash Flows. June 30, 2024 June 30, 2023 (in thousands) Cash and cash equivalents $ 26,430 $ 28,662 Restricted cash equivalents 1 3,117 — Total cash and cash equivalents and restricted cash equivalents $ 29,547 $ 28,662 1. On February 2, 2024, the Company entered into a Collateral Trust Agreement with the Company’s third-party insurer and a trustee whereby investments or money market funds are held in a trust account to benefit the insurer and are restricted for that purpose. Restricted cash equivalents represent funds invested in money market accounts as of June 30, 2024. The trust account was set up in conjunction with a reduction in the Company’s letter of credit collateral obligation for insurance obligations.

Revision of Prior Period Fina_2

Revision of Prior Period Financial Statements (Tables)	6 Months Ended
Revision of Prior Period Financial Statements (Tables)	Jun. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Schedule of Correction of Error Statements	The effect of the correction of the error noted above on the Company’s Consolidated Statements of Comprehensive (Loss) Income for the three and six months ended June 30, 2023 is as follows: Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 As reported Adjustment Revised As reported Adjustment Revised (in thousands, except per share amounts) Costs of services provided $ 367,728 $ 476 $ 368,204 $ 728,706 $ 1,877 $ 730,583 Income before taxes $ 11,410 $ (476) $ 10,934 $ 28,966 $ (1,877) $ 27,089 Income tax provision $ 2,812 $ (132) $ 2,680 $ 7,684 $ (520) $ 7,164 Net income $ 8,598 $ (344) $ 8,254 $ 21,282 $ (1,357) $ 19,925 Basic earnings per common share $ 0.12 $ (0.01) $ 0.11 $ 0.29 $ (0.02) $ 0.27 Diluted earnings per common share $ 0.12 $ (0.01) $ 0.11 $ 0.29 $ (0.02) $ 0.27

Accounts and Notes Receivable (

Accounts and Notes Receivable (Tables)	6 Months Ended
Accounts and Notes Receivable (Tables)	Jun. 30, 2024
Receivables [Abstract]
Schedule of Accounts and Notes Receivable	The Company’s accounts and notes receivable balances consisted of the following: June 30, 2024 December 31, 2023 (in thousands) Short-term Accounts and notes receivable $ 511,017 $ 470,759 Allowance for doubtful accounts (112,133) (87,250) Total net short-term accounts and notes receivable $ 398,884 $ 383,509 Long-term Notes receivable $ 24,023 $ 29,281 Allowance for doubtful accounts (3,152) (4,449) Total net long-term notes receivable $ 20,871 $ 24,832 Total net accounts and notes receivable $ 419,755 $ 408,341

Allowance for Doubtful Accoun_2

Allowance for Doubtful Accounts (Tables)	6 Months Ended
Allowance for Doubtful Accounts (Tables)	Jun. 30, 2024
Receivables [Abstract]
Schedule of Notes Receivable Disaggregated by Vintage Year	The following table presents the Company’s three tiers of notes receivable further disaggregated by year of origination as of June 30, 2024 and write-off activity for the six months ended June 30, 2024. Notes receivable Amortized cost basis by origination year 2024 2023 2022 2021 2020 Prior Total (in thousands) Notes receivable Standard notes receivable $ 7,733 $ 8,515 $ 19,482 $ — $ — $ — $ 35,730 Delinquent notes receivable $ — $ 6,460 $ 2,287 $ 774 $ 1,491 $ 21,336 $ 32,348 Elevated risk notes receivable $ — $ — $ — $ 7,378 $ — $ — $ 7,378 Current-period gross write-offs $ — $ — $ 41 $ — $ — $ 28 $ 69 Current-period recoveries — — — — — — — Current-period net write-offs $ — $ — $ 41 $ — $ — $ 28 $ 69
Schedule of Age Analysis of Past-Due Note Receivable	The following table provides information as to the status of payment on the Company’s notes receivable which were past due as of June 30, 2024. Age analysis of past-due notes receivable as of June 30, 2024 0 - 90 Days 91 - 180 Days Greater than 181 Days Total (in thousands) Notes receivable Standard notes receivable $ 585 $ — $ — $ 585 Delinquent notes receivable $ 1,797 $ 9,759 $ 16,887 $ 28,443 Elevated risk notes receivable $ 569 $ 569 $ 2,087 $ 3,225 $ 2,951 $ 10,328 $ 18,974 $ 32,253
Schedule of Changes in Allowance for Doubtful Accounts	The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the three months ended June 30, 2024 and 2023. Allowance for doubtful accounts Portfolio Segment: March 31, 2024 Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 84,087 $ (11,955) $ 31,561 $ 103,693 Notes receivable Standard notes receivable $ 3,047 $ — $ (60) $ 2,987 Delinquent notes receivable 3,698 (69) 221 3,850 Elevated risk notes receivable 4,755 — — 4,755 Total notes receivable $ 11,500 $ (69) $ 161 $ 11,592 Total accounts and notes receivable $ 95,587 $ (12,024) $ 31,722 $ 115,285 1. Write-offs are shown net of recoveries. During the three months ended June 30, 2024, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. Allowance for doubtful accounts Portfolio segment: March 31, Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 68,407 $ (8,365) $ 10,378 $ 70,420 Notes receivable Standard notes receivable $ 6,425 $ (101) $ 684 $ 7,008 Elevated risk notes receivable 2,035 (2) 201 2,234 Total notes receivable $ 8,460 $ (103) $ 885 $ 9,242 Total accounts and notes receivable $ 76,867 $ (8,468) $ 11,263 $ 79,662 1. Write-offs are shown net of recoveries. During the three months ended June 30, 2023, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the six months ended June 30, 2024 and 2023. Delinquent notes receivable were not considered a separate portfolio segment at December 31, 2023. The amount presented in the table below for the allowance for doubtful accounts for delinquent notes receivable was included within the standard notes receivable portfolio at December 31, 2023. Allowance for doubtful accounts Portfolio Segment: December 31, 2023 1 Write-Offs 2 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 80,819 $ (12,988) $ 35,862 $ 103,693 Notes receivable Standard notes receivable $ 3,510 $ — $ (523) $ 2,987 Delinquent notes receivable 2,615 (69) 1,304 3,850 Elevated risk notes receivable 4,755 — — 4,755 Total notes receivable $ 10,880 $ (69) $ 781 $ 11,592 Total accounts and notes receivable $ 91,699 $ (13,057) $ 36,643 $ 115,285 1. The December 31, 2023 balance includes transfers of $2.6 million from the standard notes receivable portfolio segment to the delinquent notes receivable portfolio segment. 2. Write-offs are shown net of recoveries. During the six months ended June 30, 2024, the Company collected $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. Allowance for doubtful accounts Portfolio segment: December 31, Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 66,601 $ (11,818) $ 15,637 $ 70,420 Notes receivable Standard notes receivable $ 6,052 $ (101) $ 1,057 $ 7,008 Elevated risk notes receivable 811 (53) 1,476 2,234 Total notes receivable $ 6,863 $ (154) $ 2,533 $ 9,242 Total accounts and notes receivable $ 73,464 $ (11,972) $ 18,170 $ 79,662 1. Write-offs are shown net of recoveries. During the six months ended June 30, 2023, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible.
Schedule of Changes in Allowance for Notes Receivable	The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the three months ended June 30, 2024 and 2023. Allowance for doubtful accounts Portfolio Segment: March 31, 2024 Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 84,087 $ (11,955) $ 31,561 $ 103,693 Notes receivable Standard notes receivable $ 3,047 $ — $ (60) $ 2,987 Delinquent notes receivable 3,698 (69) 221 3,850 Elevated risk notes receivable 4,755 — — 4,755 Total notes receivable $ 11,500 $ (69) $ 161 $ 11,592 Total accounts and notes receivable $ 95,587 $ (12,024) $ 31,722 $ 115,285 1. Write-offs are shown net of recoveries. During the three months ended June 30, 2024, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. Allowance for doubtful accounts Portfolio segment: March 31, Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 68,407 $ (8,365) $ 10,378 $ 70,420 Notes receivable Standard notes receivable $ 6,425 $ (101) $ 684 $ 7,008 Elevated risk notes receivable 2,035 (2) 201 2,234 Total notes receivable $ 8,460 $ (103) $ 885 $ 9,242 Total accounts and notes receivable $ 76,867 $ (8,468) $ 11,263 $ 79,662 1. Write-offs are shown net of recoveries. During the three months ended June 30, 2023, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. The following tables provide a summary of the changes in the Company’s allowance for doubtful accounts on a portfolio segment basis for the six months ended June 30, 2024 and 2023. Delinquent notes receivable were not considered a separate portfolio segment at December 31, 2023. The amount presented in the table below for the allowance for doubtful accounts for delinquent notes receivable was included within the standard notes receivable portfolio at December 31, 2023. Allowance for doubtful accounts Portfolio Segment: December 31, 2023 1 Write-Offs 2 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 80,819 $ (12,988) $ 35,862 $ 103,693 Notes receivable Standard notes receivable $ 3,510 $ — $ (523) $ 2,987 Delinquent notes receivable 2,615 (69) 1,304 3,850 Elevated risk notes receivable 4,755 — — 4,755 Total notes receivable $ 10,880 $ (69) $ 781 $ 11,592 Total accounts and notes receivable $ 91,699 $ (13,057) $ 36,643 $ 115,285 1. The December 31, 2023 balance includes transfers of $2.6 million from the standard notes receivable portfolio segment to the delinquent notes receivable portfolio segment. 2. Write-offs are shown net of recoveries. During the six months ended June 30, 2024, the Company collected $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible. Allowance for doubtful accounts Portfolio segment: December 31, Write-Offs 1 Bad Debt Expense June 30, (in thousands) Accounts receivable $ 66,601 $ (11,818) $ 15,637 $ 70,420 Notes receivable Standard notes receivable $ 6,052 $ (101) $ 1,057 $ 7,008 Elevated risk notes receivable 811 (53) 1,476 2,234 Total notes receivable $ 6,863 $ (154) $ 2,533 $ 9,242 Total accounts and notes receivable $ 73,464 $ (11,972) $ 18,170 $ 79,662 1. Write-offs are shown net of recoveries. During the six months ended June 30, 2023, the Company collected less than $0.1 million of accounts and notes receivable which had previously been written-off as uncollectible.

Changes in Accumulated Other _2

Changes in Accumulated Other Comprehensive Loss by Component (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	The following table provides a summary of the changes in accumulated other comprehensive loss for the six months ended June 30, 2024 and 2023: Unrealized Gains and Losses on Available-for-Sale Securities¹ Six Months Ended June 30, 2024 2023 (in thousands) Accumulated other comprehensive loss — beginning balance $ (1,844) $ (3,477) Other comprehensive (loss) income before reclassifications (1,040) 344 Income reclassified from other comprehensive loss² 267 3 Net current period other comprehensive (loss) income³ (773) 347 Accumulated other comprehensive loss — ending balance $ (2,617) $ (3,130) 1. All amounts are net of tax. 2. Realized gains and losses were recorded pre-tax within “Investment and other income, net” in the Consolidated Statements of Comprehensive (Loss) Income. For the six months ended June 30, 2024 and 2023, the Company recorded realized losses of $0.3 million and less than $0.1 million, respectively from the sale of available-for-sale securities. Refer to Note 10—Fair Value Measurements herein for further information. 3. For the six months ended June 30, 2024 and 2023, the changes in other comprehensive loss were net of a tax benefit of $0.1 million and an expense of $0.1 million, respectively.
Schedule of Reclassification out of Accumulated Other Comprehensive Loss	The following table provides a rollforward of amounts reclassified from accumulated other comprehensive loss to realized losses for the three and six months ended June 30, 2024 and 2023: Amounts Reclassified from Accumulated Other Comprehensive Loss 2024 2023 (in thousands) Three Months Ended June 30, Losses from the sale of available-for-sale securities $ (126) $ (2) Tax benefit 26 1 Net loss reclassified from accumulated other comprehensive loss $ (100) $ (1) Six Months Ended June 30, Losses from the sale of available-for-sale securities $ (337) $ (4) Tax benefit 70 1 Net losses reclassified from accumulated other comprehensive loss $ (267) $ (3)

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
Property and Equipment (Tables)	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The following table sets forth the amounts of property and equipment by each class of depreciable asset as of June 30, 2024 and December 31, 2023: June 30, 2024 December 31, 2023 (in thousands) Housekeeping and dietary equipment $ 17,015 $ 15,764 Computer hardware and software 7,059 6,870 Operating lease — right-of-use assets 28,879 27,099 Other 1 901 1,070 Total property and equipment, at cost 53,854 50,803 Less accumulated depreciation 2 24,014 22,029 Total property and equipment, net $ 29,840 $ 28,774 1. Includes furniture and fixtures, leasehold improvements and autos and trucks. 2. Includes $10.7 million and $9.4 million related to accumulated depreciation on Operating lease – right-of-use assets as of June 30, 2024 and December 31, 2023, respectively.

Leases (Tables)

Leases (Tables)	6 Months Ended
Leases (Tables)	Jun. 30, 2024
Leases [Abstract]
Schedule of Components of Lease Expense	Components of lease expense required by ASC 842 are presented below for the three and six months ended June 30, 2024 and 2023. Three Months Ended June 30, 2024 2023 (in thousands) Lease cost Operating lease cost $ 1,945 $ 1,444 Short-term lease cost 323 422 Variable lease cost 551 633 Total lease cost $ 2,819 $ 2,499 Six Months Ended June 30, 2024 2023 (in thousands) Lease cost Operating lease cost $ 3,782 $ 2,831 Short-term lease cost 494 654 Variable lease cost 841 1,083 Total lease cost $ 5,117 $ 4,568
Schedule of Supplemental Information Required by ASC 842	Supplemental information required by ASC 842 is presented below for the six months ended June 30, 2024 and 2023. Six Months Ended June 30, 2024 2023 (dollar amounts in thousands) Other information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 3,958 $ 3,110 Weighted-average remaining lease term — operating leases 2.9 years 3.7 years Weighted-average discount rate — operating leases 6.9 % 6.0 %
Schedule of Future Minimum Lease Payments	The following is a schedule by calendar year of future minimum lease payments under operating leases that have remaining terms as of June 30, 2024: Period/Year Operating Leases (in thousands) July 1 to December 31, 2024 $ 4,058 2025 7,964 2026 5,201 2027 1,797 2028 1,389 2029 116 Thereafter — Total minimum lease payments $ 20,525 Less: imputed interest 1,917 Present value of lease liabilities $ 18,608

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	6 Months Ended
Other Intangible Assets (Tables)	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Estimated Amortization Expense for Intangibles Subject to Amortization	The following table sets forth the estimated amortization expense for intangibles subject to amortization for the remainder of 2024, the following five fiscal years and thereafter: Period/Year Total Amortization Expense (in thousands) July 1 to December 31, 2024 $ 1,343 2025 $ 2,685 2026 $ 2,666 2027 $ 1,196 2028 $ 613 2029 $ 508 Thereafter $ 1,774

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
Fair Value Measurements (Tables)	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Contractual Maturities of Debt Securities	The following table summarizes the contractual maturities of debt securities held at June 30, 2024 and December 31, 2023, which are classified as “Marketable securities, at fair value” and “Restricted marketable securities, at fair value” in the Consolidated Balance Sheets: Debt Securities — Available-for-Sale Contractual maturity: June 30, 2024 December 31, 2023 (in thousands) Marketable securities, at fair value Maturing in one year or less $ 1,007 $ 6,324 Maturing in second year through fifth year 27,296 34,939 Maturing in sixth year through tenth year 32,934 39,309 Maturing after ten years 17,897 12,559 Total marketable securities, at fair value $ 79,134 $ 93,131 Restricted marketable securities, at fair value Maturing in one year or less $ 1,047 $ — Maturing in second year through fifth year 7,058 — Maturing in sixth year through tenth year 12,895 — Maturing after ten years 1,022 — Total restricted marketable securities, at fair value $ 22,022 $ — Total debt securities — available-for-sale $ 101,156 $ 93,131
Schedule of Amortized Cost, Unrealized Gains and Losses, and Estimated Fair Value of Debt Securities	The following table shows the amortized cost, unrealized gains and losses, and estimated fair value of the Company’s debt securities as of June 30, 2024 and December 31, 2023: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Credit Impairment Losses 1 (in thousands) June 30, 2024 Type of security: Marketable securities Municipal bonds — taxable $ 9,242 $ 18 $ (752) $ 8,508 $ — Municipal bonds — non-taxable 73,216 49 (2,639) 70,626 — Total marketable securities $ 82,458 $ 67 $ (3,391) $ 79,134 $ — Restricted marketable securities U.S. treasury bonds $ 6,888 $ 13 $ — $ 6,901 $ — U.S. government agency bonds 1,207 2 — 1,209 — International fixed income bonds 625 — (1) 624 — Corporate bonds 5,134 5 (2) 5,137 — Municipal bonds — taxable 8,156 16 (21) 8,151 — Total restricted marketable securities $ 22,010 $ 36 $ (24) $ 22,022 $ — Total debt securities — available-for-sale $ 104,468 $ 103 $ (3,415) $ 101,156 $ — December 31, 2023 Type of security: Municipal bonds — non-taxable $ 95,466 $ 387 $ (2,722) $ 93,131 $ — Total debt securities — available-for-sale $ 95,466 $ 387 $ (2,722) $ 93,131 $ — 1. The Company performs a credit impairment loss assessment quarterly on an individual security basis. As of June 30, 2024 and December 31, 2023, no allowance for credit loss has been recognized as the issuers of these securities have not established a cause for default and various rating agencies have reaffirmed each security’s investment grade status. The fair value of these securities have fluctuated since the purchase date as market interest rates fluctuate. The Company does not intend to sell these securities and it is more likely than not that the Company will not be required to sell before the recovery of the securities’ amortized cost basis.
Schedule of Fair Value Measurements Information for Marketable Securities and Deferred Compensation Fund Investments	The following tables provide fair value measurement information for the Company’s financial assets, including marketable securities, restricted marketable securities and deferred compensation fund investments as of June 30, 2024 and December 31, 2023: As of June 30, 2024 Fair Value Measurement Using: Carrying Amount Total Fair Value Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in thousands) Marketable securities Municipal bonds — taxable $ 8,508 $ 8,508 $ — $ 8,508 $ — Municipal bonds — non-taxable 70,626 70,626 — 70,626 — Total marketable securities $ 79,134 $ 79,134 $ — $ 79,134 $ — Restricted marketable securities U.S. treasury bonds $ 6,901 $ 6,901 $ — $ 6,901 $ — U.S. government agency bonds 1,209 1,209 — 1,209 — International fixed income bonds 624 624 — 624 — Corporate bonds 5,137 5,137 — 5,137 — Municipal bonds — taxable 8,151 8,151 — 8,151 — Total restricted marketable securities $ 22,022 $ 22,022 $ — $ 22,022 $ — Deferred compensation fund Money market 1 $ 1,933 $ 1,933 $ — $ 1,933 $ — Commodities 315 315 315 — — Fixed income 4,605 4,605 4,605 — — International 4,942 4,942 4,942 — — Large cap blend 5,794 5,794 5,794 — — Large cap growth 16,890 16,890 16,890 — — Large cap value 6,543 6,543 6,543 — — Mid cap blend 3,382 3,382 3,382 — — Real estate 350 350 350 — — Small cap blend 2,679 2,679 2,679 — — Total deferred compensation fund 2 $ 47,433 $ 47,433 $ 45,500 $ 1,933 $ — As of December 31, 2023 Fair Value Measurement Using: Carrying Total Fair Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in thousands) Marketable securities Municipal bonds — non-taxable $ 93,131 $ 93,131 $ — $ 93,131 $ — Deferred compensation fund Money market 1 $ 2,007 $ 2,007 $ — $ 2,007 $ — Commodities 298 298 298 — — Fixed income 4,254 4,254 4,254 — — International 4,621 4,621 4,621 — — Large cap blend 5,053 5,053 5,053 — — Large cap growth 13,886 13,886 13,886 — — Large cap value 5,964 5,964 5,964 — — Mid cap blend 3,192 3,192 3,192 — — Real estate 374 374 374 — — Small cap blend 2,664 2,664 2,664 — — Deferred compensation fund 2 $ 42,313 $ 42,313 $ 40,306 $ 2,007 $ — 1. The fair value of the money market fund is based on the NAV of the shares held by the plan at the end of the period. The money market fund includes short-term United States dollar denominated money market instruments and the NAV is determined by the custodian of the fund. The money market fund can be redeemed at its NAV at the measurement date as there are no significant restrictions on the ability to sell this investment. 2. As of June 30, 2024 and December 31, 2023, $1.4 million and $1.5 million of short-term deferred compensation funding is included within “Prepaid expenses and other assets” in the Company’s Consolidated Balance Sheets, respectively. Such amounts of short-term deferred compensation funding represent investments expected to be liquidated and paid within 12 months of June 30, 2024 and December 31, 2023, respectively.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
Share-Based Compensation (Tables)	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense	The components of the Company’s share-based compensation expense for the six months ended June 30, 2024 and 2023 are as follows: Six Months Ended June 30, 2024 2023 (in thousands) Stock options $ 353 $ 463 Restricted stock, restricted stock units and deferred stock units 3,501 3,223 Performance stock units 665 565 Employee Stock Purchase Plan 78 158 Total pre-tax share-based compensation expense charged against income $ 4,597 $ 4,409 The following table summarizes the components of share-based compensation expense included within the Consolidated Statements of Comprehensive (Loss) Income for the six months ended June 30, 2024 and 2023: Six Months Ended June 30, 2024 2023 (in thousands) Selling, general and administrative expense $ 4,572 $ 4,363 Costs of services provided 25 46 Total share-based compensation expense $ 4,597 $ 4,409
Schedule of Stock Options Outstanding	A summary of stock options outstanding under the Amended 2020 Plan and the 2012 Plan as of December 31, 2023 and changes during the six months ended June 30, 2024 are as follows: Stock Options Outstanding Number of Shares Weighted Average Exercise Price (in thousands) December 31, 2023 2,438 $ 30.43 Granted 290 $ 10.36 Exercised — $ — Forfeited (1) $ 24.43 Expired (179) $ 28.45 June 30, 2024 2,548 $ 28.29
Schedule of Assumption for Fair Value of Options Granted	The fair value of stock option awards granted during the six months ended June 30, 2024 and 2023 was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions: Six Months Ended June 30, 2024 2023 Risk-free interest rate 3.9 % 4.0 % Weighted average expected life 7.0 years 6.9 years Expected volatility 40.5 % 39.5 % Dividend yield — % — %
Schedule of Other Information about Stock Options	The following table summarizes other information about the stock options at June 30, 2024: June 30, 2024 (amounts in thousands, except per share data) Outstanding: Aggregate intrinsic value $ 64 Weighted average remaining contractual life 4.9 years Exercisable: Number of options 1,756 Weighted average exercise price $ 33.93 Aggregate intrinsic value $ — Weighted average remaining contractual life 3.4 years
Schedule of Outstanding Restricted Stock Units	A summary of the outstanding restricted stock units as of December 31, 2023 and changes during the six months ended June 30, 2024 is as follows: Restricted Stock Units Number Weighted Average Grant Date Fair Value (in thousands) December 31, 2023 1,102 $ 18.57 Granted 770 $ 10.38 Vested (297) $ 21.68 Forfeited (17) $ 14.17 June 30, 2024 1,558 $ 13.97
Schedule of Outstanding Performance Stock Units	A summary of the outstanding PSUs as of December 31, 2023 and changes during the six months ended June 30, 2024 is as follows: Performance Stock Units Number Weighted Average Grant Date Fair Value (in thousands) December 31, 2023 175 $ 21.52 Granted 118 $ 11.85 Vested — $ — Forfeited (35) $ 34.52 June 30, 2024 258 $ 15.31
Schedule of Options Granted Under Employee Stock Purchase Plan	The expense associated with the options granted under the ESPP during the six months ended June 30, 2024 and 2023 was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions: Six Months Ended June 30, 2024 2023 Risk-free interest rate 4.8% 4.8% Weighted average expected life (years) 1.0 1.0 Expected volatility 37.1% 42.9% Dividend yield —% 7.1%
Schedule of Supplemental Employee Retirement Plan	The following table summarizes information about the SERP during the six months ended June 30, 2024 and 2023: Six Months Ended June 30, 2024 2023 (in thousands) SERP expense 1 $ 355 $ 298 Unrealized gain recorded in SERP liability account $ 5,350 $ 3,871 1. Both the SERP match and the deferrals are included in the “ Selling, general and administrative expense ”

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
Segment Information (Tables)	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Information	Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (in thousands) Revenues Housekeeping $ 191,006 $ 190,817 $ 381,565 $ 384,336 Dietary 235,282 228,114 468,156 451,825 Total $ 426,288 $ 418,931 $ 849,721 $ 836,161 Income before income taxes Housekeeping $ 17,017 $ 16,608 $ 35,459 $ 36,661 Dietary 14,932 12,443 32,559 27,110 Corporate and eliminations 1 (33,935) (18,117) (48,690) (36,682) Total $ (1,986) $ 10,934 $ 19,328 $ 27,089 1. Primarily represents corporate office costs and related overhead, recording of certain inventories and supplies and workers’ compensation costs at the reportable segment level which use accounting methods that differ from those used at the corporate level, as well as consolidated subsidiaries’ operating expenses that are not allocated to the reportable segments, net of investment and other income and interest expense.

Basic (Loss) Earnings Per Com_2

Basic (Loss) Earnings Per Common Share (Tables)	6 Months Ended
Basic (Loss) Earnings Per Common Share (Tables)	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Weighted Average Basic and Diluted Common Shares Outstanding	The table below reconciles the weighted-average basic and diluted common shares outstanding: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (in thousands, except for per share amounts) Numerator for basic and diluted (loss) earnings per share: Net (loss) income $ (1,788) $ 8,254 $ 13,521 $ 19,925 Denominator Weighted average number of common shares outstanding - basic 73,853 74,478 73,889 74,488 Effect of dilutive securities 1 — 89 159 55 Weighted average number of common shares outstanding - diluted 73,853 74,567 74,048 74,543 Basic (loss) earnings per share: $ (0.02) $ 0.11 $ 0.18 $ 0.27 Diluted (loss) earnings per share: $ (0.02) $ 0.11 $ 0.18 $ 0.27 1.
Schedule of Anti-dilutive Outstanding Equity Awards Under Share Based Compensation Plans	Anti-dilutive outstanding equity awards under share-based compensation plans were as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (in thousands) Anti-dilutive 3,000 3,077 2,844 2,721

Description of Business and S_4

Description of Business and Significant Accounting Policies - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($) institution shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) segment institution shares	Jun. 30, 2023 USD ($)	Jun. 18, 2024 shares	Jun. 17, 2024 shares	Dec. 31, 2023 institution shares
Schedule of Accounting Policies [Line Items]
Renewal term			1 year
Number of reportable segments \| segment			2
Payment terms			The Company’s payment terms with customers on promissory notes can vary based on several factors and the circumstances of each promissory note, however most promissory notes mature over 1 to 4 years. Similar to accounts receivable, each reporting period the Company evaluates the collectability of outstanding notes receivable balances and records an allowance for doubtful accounts representing an estimate of future expected credit losses
Amortization period of inventories and supplies			24 months
Goodwill and intangible asset impairment			$ 0	$ 0
Common stock authorized (in shares) \| shares	200,000,000		200,000,000		200,000,000	100,000,000	200,000,000
Number of financial institutions holding cash and cash equivalents and marketable securities \| institution	2		2				1
Revenue	$ 426,288,000	$ 418,931,000	$ 849,721,000	836,161,000
Significant Customer \| Consolidated revenues \| Genesis
Schedule of Accounting Policies [Line Items]
Revenue	$ 37,900,000	$ 47,600,000	$ 76,700,000	$ 95,700,000
Percent of revenue	8.90%	11.40%	9%	11.40%
Health Care Consulting Company
Schedule of Accounting Policies [Line Items]
Investments in equity securities	$ 2,800,000		$ 2,800,000
Ownership share	25%		25%
Minimum
Schedule of Accounting Policies [Line Items]
Cancellation notice period			30 days
Initial period preceding cancellation notice			60 days
Maximum
Schedule of Accounting Policies [Line Items]
Cancellation notice period			90 days
Initial period preceding cancellation notice			120 days

Description of Business and S_5

Description of Business and Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 26,430	$ 54,330	$ 28,662
Restricted cash equivalents	3,117		0
Total cash and cash equivalents and restricted cash equivalents	$ 29,547	$ 54,330	$ 28,662	$ 26,279

Revision of Prior Period Fina_3

Revision of Prior Period Financial Statements - Schedule of Correction of Error Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Costs of services provided	$ 384,742		$ 368,204		$ 743,653	$ 730,583
(Loss) income before taxes	(1,986)		10,934		19,328	27,089
Income tax (benefit) provision	(198)		2,680		5,807	7,164
Net (loss) income	$ (1,788)	$ 15,309	$ 8,254	$ 11,671	$ 13,521	$ 19,925
Basic earnings per common share (in dollars per share)	$ (0.02)		$ 0.11		$ 0.18	$ 0.27
Diluted earnings per common share (in dollars per share)	$ (0.02)		$ 0.11		$ 0.18	$ 0.27
Reduction in retained earnings	$ (198,595)				$ (198,595)		$ (185,010)
As reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Costs of services provided			$ 367,728			$ 728,706
(Loss) income before taxes			11,410			28,966
Income tax (benefit) provision			2,812			7,684
Net (loss) income			$ 8,598			$ 21,282
Basic earnings per common share (in dollars per share)			$ 0.12			$ 0.29
Diluted earnings per common share (in dollars per share)			$ 0.12			$ 0.29
Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Costs of services provided			$ 476			$ 1,877
(Loss) income before taxes			(476)			(1,877)
Income tax (benefit) provision			(132)			(520)
Net (loss) income			$ (344)			$ (1,357)
Basic earnings per common share (in dollars per share)			$ (0.01)			$ (0.02)
Diluted earnings per common share (in dollars per share)			$ (0.01)			$ (0.02)
Reduction in retained earnings								$ 7,900

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 426,288	$ 418,931	$ 849,721	$ 836,161
Renewal term			1 year
Description of timing			The Company’s contracts with customers typically provide for an initial term of one year, with renewable one year service terms, cancellable by either party upon 30 to 90 days’ notice after an initial period of 60 to 120 days.
Revenue from contract with customer, initial term			1 year
Transferred at point in time
Disaggregation of Revenue [Line Items]
Contract liabilities					$ 3,200
Transferred at point in time \| Customers pending executed contract
Disaggregation of Revenue [Line Items]
Contract liabilities	100		$ 100
Transferred over time
Disaggregation of Revenue [Line Items]
Contract liabilities	1,300		1,300
Revenue recognized from contract liability			$ 1,900
Transferred over time \| Customers pending executed contract
Disaggregation of Revenue [Line Items]
Contract liabilities					$ 100
Minimum
Disaggregation of Revenue [Line Items]
Cancellation notice period			30 days
Initial period preceding cancellation notice			60 days
Maximum
Disaggregation of Revenue [Line Items]
Cancellation notice period			90 days
Initial period preceding cancellation notice			120 days
Housekeeping
Disaggregation of Revenue [Line Items]
Revenue	191,006	190,817	$ 381,565	$ 384,336
Housekeeping \| Revenue \| Service concentration
Disaggregation of Revenue [Line Items]
Percent of revenue			44.90%	46%
Dietary
Disaggregation of Revenue [Line Items]
Revenue	$ 235,282	$ 228,114	$ 468,156	$ 451,825
Dietary \| Revenue \| Service concentration
Disaggregation of Revenue [Line Items]
Percent of revenue			55.10%	54%

Accounts and Notes Receivable -

Accounts and Notes Receivable - Schedule of Accounts and Notes Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Short-term
Accounts and notes receivable	$ 511,017	$ 470,759
Allowance for doubtful accounts	(112,133)	(87,250)
Total net short-term accounts and notes receivable	398,884	383,509
Long-term
Notes receivable	24,023	29,281
Allowance for doubtful accounts	(3,152)	(4,449)
Total net long-term notes receivable	20,871	24,832
Total net accounts and notes receivable	$ 419,755	$ 408,341

Allowance for Doubtful Accoun_3

Allowance for Doubtful Accounts - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Financing Receivable, Allowance for Credit Loss [Line Items]
Interest income	$ 600	$ 700	$ 1,700	$ 1,300
Bad debt provision	31,561	$ 10,378	$ 35,862	$ 15,637
LaVie Care Centers, LLC
Financing Receivable, Allowance for Credit Loss [Line Items]
Bad debt provision	$ 17,600

Allowance for Doubtful Accoun_4

Allowance for Doubtful Accounts - Notes Receivable Disaggregated by Vintage Year (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Current-period gross write-offs
2024			$ 0
2023			0
2022			41
2021			0
2020			0
Prior			28
Total			69
Current-period recoveries
2024			0
2023			0
2022			0
2021			0
2020			0
Prior			0
Total			0
Current-period net write-offs
2024			0
2023			0
2022			41
2021			0
2020			0
Prior			28
Total	$ 69	$ 103	69	$ 154
Standard notes receivable
Financing Receivable, Credit Quality Indicator [Line Items]
2024	7,733		7,733
2023	8,515		8,515
2022	19,482		19,482
2021	0		0
2020	0		0
Prior	0		0
Total	35,730		35,730
Current-period net write-offs
Total	0	101	0	101
Delinquent notes receivable
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0		0
2023	6,460		6,460
2022	2,287		2,287
2021	774		774
2020	1,491		1,491
Prior	21,336		21,336
Total	32,348		32,348
Current-period net write-offs
Total	69		69
Elevated risk notes receivable
Financing Receivable, Credit Quality Indicator [Line Items]
2024	0		0
2023	0		0
2022	0		0
2021	7,378		7,378
2020	0		0
Prior	0		0
Total	7,378		7,378
Current-period net write-offs
Total	$ 0	$ 2	$ 0	$ 53

Allowance for Doubtful Accoun_5

Allowance for Doubtful Accounts - Age Analysis of Past-Due Note Receivable (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Total
Financing Receivable, Past Due [Line Items]
Notes receivable	$ 32,253
0 - 90 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	2,951
91 - 180 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	10,328
Greater than 181 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	18,974
Standard notes receivable
Financing Receivable, Past Due [Line Items]
Notes receivable	35,730
Standard notes receivable \| Total
Financing Receivable, Past Due [Line Items]
Notes receivable	585
Standard notes receivable \| 0 - 90 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	585
Standard notes receivable \| 91 - 180 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	0
Standard notes receivable \| Greater than 181 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	0
Delinquent notes receivable
Financing Receivable, Past Due [Line Items]
Notes receivable	32,348
Delinquent notes receivable \| Total
Financing Receivable, Past Due [Line Items]
Notes receivable	28,443
Delinquent notes receivable \| 0 - 90 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	1,797
Delinquent notes receivable \| 91 - 180 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	9,759
Delinquent notes receivable \| Greater than 181 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	16,887
Elevated risk notes receivable
Financing Receivable, Past Due [Line Items]
Notes receivable	7,378
Elevated risk notes receivable \| Total
Financing Receivable, Past Due [Line Items]
Notes receivable	3,225
Elevated risk notes receivable \| 0 - 90 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	569
Elevated risk notes receivable \| 91 - 180 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	569
Elevated risk notes receivable \| Greater than 181 Days
Financing Receivable, Past Due [Line Items]
Notes receivable	$ 2,087

Allowance for Doubtful Accoun_6

Allowance for Doubtful Accounts - Schedule of Changes in Allowance for Notes Receivable (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Accounts receivable
Allowance for doubtful accounts, beginning balance	$ 84,087	$ 68,407	$ 80,819	$ 66,601
Write-Offs	(11,955)	(8,365)	(12,988)	(11,818)
Bad Debt Expense	31,561	10,378	35,862	15,637
Allowance for doubtful accounts, ending balance	103,693	70,420	103,693	70,420
Notes receivable
Allowance for doubtful accounts, beginning balance	11,500	8,460	10,880	6,863
Write-Offs	(69)	(103)	(69)	(154)
Bad Debt Expense	161	885	781	2,533
Allowance for doubtful accounts, ending balance	11,592	9,242	11,592	9,242
Total accounts and notes receivable
Allowance for doubtful accounts, beginning balance	95,587	76,867	91,699	73,464
Write-Offs	(12,024)	(8,468)	(13,057)	(11,972)
Bad Debt Expense	31,722	11,263	36,643	18,170
Allowance for doubtful accounts, ending balance	115,285	79,662	115,285	79,662
Accounts receivable recovered after write off	100	100	100	100
LaVie Care Centers, LLC
Accounts receivable
Bad Debt Expense	17,600
Standard notes receivable
Notes receivable
Allowance for doubtful accounts, beginning balance	3,047	6,425	3,510	6,052
Write-Offs	0	(101)	0	(101)
Bad Debt Expense	(60)	684	(523)	1,057
Allowance for doubtful accounts, ending balance	2,987	7,008	2,987	7,008
Delinquent notes receivable
Notes receivable
Allowance for doubtful accounts, beginning balance	3,698		2,615
Write-Offs	(69)		(69)
Bad Debt Expense	221		1,304
Allowance for doubtful accounts, ending balance	3,850		3,850
Total accounts and notes receivable
Financing receivable, allowance for credit loss, transfers					$ 2,600
Elevated risk notes receivable
Notes receivable
Allowance for doubtful accounts, beginning balance	4,755	2,035	4,755	811
Write-Offs	0	(2)	0	(53)
Bad Debt Expense	0	201	0	1,476
Allowance for doubtful accounts, ending balance	$ 4,755	$ 2,234	$ 4,755	$ 2,234

Changes in Accumulated Other _3

Changes in Accumulated Other Comprehensive Loss by Component - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Accumulated other comprehensive income
Beginning balance	$ 474,581	$ 456,616	$ 418,279
Other comprehensive (loss) income before reclassifications		(1,040)	344
Income reclassified from other comprehensive loss		267	3
Net current period other comprehensive (loss) income		(773)	347
Ending balance	471,423	471,423	441,339
Realized loss	100	300	100
Changes in other comprehensive (loss) income, tax benefit (expense)		100	(100)
Accumulated Other Comprehensive Loss, net of taxes
Accumulated other comprehensive income
Beginning balance	(2,172)	(1,844)	(3,477)
Ending balance	$ (2,617)	$ (2,617)	$ (3,130)

Changes in Accumulated Other _4

Changes in Accumulated Other Comprehensive Loss by Component - Reclassification Adjustments (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Losses from the sale of available-for-sale securities	$ 2,621		$ 3,551		$ 8,320	$ 6,653
Tax benefit	198		(2,680)		(5,807)	(7,164)
Net losses reclassified from accumulated other comprehensive loss	(1,788)	$ 15,309	8,254	$ 11,671	13,521	19,925
Amounts Reclassified from Accumulated Other Comprehensive Loss
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net losses reclassified from accumulated other comprehensive loss	(100)		(1)		(267)	(3)
Losses from the sale of available-for-sale securities \| Amounts Reclassified from Accumulated Other Comprehensive Loss
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Losses from the sale of available-for-sale securities	(126)		(2)		(337)	(4)
Tax benefit	$ 26		$ 1		$ 70	$ 1

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Total property and equipment, net		Total property and equipment, net		Total property and equipment, net
Operating lease — right-of-use assets	$ 28,879		$ 28,879		$ 27,099
Total property and equipment, at cost	53,854		53,854		50,803
Less accumulated depreciation	24,014		24,014		22,029
Total property and equipment, net	29,840		29,840		28,774
Accumulated depreciation on operating lease right-of-use assets	10,700		10,700		9,400
Depreciation	3,000	$ 2,400	5,900	$ 4,900
ROU assets depreciation	1,900	$ 1,600	3,800	$ 2,800
Housekeeping and dietary equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,015		17,015		15,764
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,059		7,059		6,870
Other
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 901		$ 901		$ 1,070

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Lessee, Lease, Description [Line Items]
Termination option			1 year
ROU assets and lease liabilities reduction due to cancellation	$ 0.3	$ 0.4	$ 0.5	$ 1.1
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year		1 year
Extension option	1 year		1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	5 years		5 years
Extension option	5 years		5 years

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Lease cost
Operating lease cost	$ 1,945	$ 1,444	$ 3,782	$ 2,831
Short-term lease cost	323	422	494	654
Variable lease cost	551	633	841	1,083
Total lease cost	$ 2,819	$ 2,499	5,117	4,568
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases			$ 3,958	$ 3,110
Weighted-average remaining lease term — operating leases	2 years 10 months 24 days	3 years 8 months 12 days	2 years 10 months 24 days	3 years 8 months 12 days
Weighted-average discount rate — operating leases	6.90%	6%	6.90%	6%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Leases [Abstract]
July 1 to December 31, 2024	$ 4,058
2025	7,964
2026	5,201
2027	1,797
2028	1,389
2029	116
Thereafter	0
Total minimum lease payments	20,525
Less: imputed interest	1,917
Present value of lease liabilities	$ 18,608

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 0.7	$ 1.2	$ 1.3	$ 2.4
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)			10 years
Trade Names
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)			13 years
Patents
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)			8 years
Noncompete Agreements
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life (in years)			4 years

Other Intangible Assets - Estim

Other Intangible Assets - Estimated Amortization Expense For Intangibles Subject To Amortization (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
July 1 to December 31, 2024	$ 1,343
2025	2,685
2026	2,666
2027	1,196
2028	613
2029	508
Thereafter	$ 1,774

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Unrealized gain (loss) on available-for-sale marketable securities, net of taxes	$ (400)	$ (900)	$ (800)	$ 300
Realized (gains) losses	500	(600)	(300)	(200)
Proceeds from available for sale municipal bonds	11,400	1,200	27,951	1,375
Realized loss	(100)		(300)	(100)
Realized gain (less than)		100
Unrealized gains related to equity securities	$ 1,300	$ 2,300	$ 5,400	$ 3,800

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Contractual Maturities of Debt Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Total marketable securities, at fair value	$ 101,156	$ 93,131
Unrestricted
Debt Securities, Available-for-Sale [Line Items]
Maturing in one year or less	1,007	6,324
Maturing in second year through fifth year	27,296	34,939
Maturing in sixth year through tenth year	32,934	39,309
Maturing after ten years	17,897	12,559
Total marketable securities, at fair value	79,134	93,131
Restricted
Debt Securities, Available-for-Sale [Line Items]
Maturing in one year or less	1,047	0
Maturing in second year through fifth year	7,058	0
Maturing in sixth year through tenth year	12,895	0
Maturing after ten years	1,022	0
Total marketable securities, at fair value	$ 22,022	$ 0

Fair Value Measurements - Marke

Fair Value Measurements - Marketable Debt Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	$ 104,468	$ 95,466
Gross Unrealized Gains	103	387
Gross Unrealized Losses	(3,415)	(2,722)
Estimated Fair Value	101,156	93,131
Credit Impairment Losses	0	0
Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	82,458
Gross Unrealized Gains	67
Gross Unrealized Losses	(3,391)
Estimated Fair Value	79,134	93,131
Credit Impairment Losses	0
Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	22,010
Gross Unrealized Gains	36
Gross Unrealized Losses	(24)
Estimated Fair Value	22,022	0
Credit Impairment Losses	0
Quoted Prices in Active Markets (Level 1) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Quoted Prices in Active Markets (Level 1) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Significant Other Observable Inputs (Level 2) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	79,134
Significant Other Observable Inputs (Level 2) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	22,022
Significant Unobservable Inputs (Level 3) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Significant Unobservable Inputs (Level 3) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Carrying Amount \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	79,134
Carrying Amount \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	22,022
Total Fair Value \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	79,134
Total Fair Value \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	22,022
Municipal bonds — taxable \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	9,242
Gross Unrealized Gains	18
Gross Unrealized Losses	(752)
Estimated Fair Value	8,508
Credit Impairment Losses	0
Municipal bonds — taxable \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	8,156
Gross Unrealized Gains	16
Gross Unrealized Losses	(21)
Estimated Fair Value	8,151
Credit Impairment Losses	0
Municipal bonds — taxable \| Quoted Prices in Active Markets (Level 1) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Municipal bonds — taxable \| Quoted Prices in Active Markets (Level 1) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Municipal bonds — taxable \| Significant Other Observable Inputs (Level 2) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	8,508
Municipal bonds — taxable \| Significant Other Observable Inputs (Level 2) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	8,151
Municipal bonds — taxable \| Significant Unobservable Inputs (Level 3) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Municipal bonds — taxable \| Significant Unobservable Inputs (Level 3) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Municipal bonds — taxable \| Carrying Amount \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	8,508
Municipal bonds — taxable \| Carrying Amount \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	8,151
Municipal bonds — taxable \| Total Fair Value \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	8,508
Municipal bonds — taxable \| Total Fair Value \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	8,151
Municipal bonds — non-taxable
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost		95,466
Gross Unrealized Gains		387
Gross Unrealized Losses		(2,722)
Estimated Fair Value		93,131
Credit Impairment Losses		0
Municipal bonds — non-taxable \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	73,216
Gross Unrealized Gains	49
Gross Unrealized Losses	(2,639)
Estimated Fair Value	70,626
Credit Impairment Losses	0
Municipal bonds — non-taxable \| Quoted Prices in Active Markets (Level 1)
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value		0
Municipal bonds — non-taxable \| Quoted Prices in Active Markets (Level 1) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Municipal bonds — non-taxable \| Significant Other Observable Inputs (Level 2)
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value		93,131
Municipal bonds — non-taxable \| Significant Other Observable Inputs (Level 2) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	70,626
Municipal bonds — non-taxable \| Significant Unobservable Inputs (Level 3)
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value		0
Municipal bonds — non-taxable \| Significant Unobservable Inputs (Level 3) \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Municipal bonds — non-taxable \| Carrying Amount
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value		93,131
Municipal bonds — non-taxable \| Carrying Amount \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	70,626
Municipal bonds — non-taxable \| Total Fair Value
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value		$ 93,131
Municipal bonds — non-taxable \| Total Fair Value \| Unrestricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	70,626
U.S. treasury bonds \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	6,888
Gross Unrealized Gains	13
Gross Unrealized Losses	0
Estimated Fair Value	6,901
Credit Impairment Losses	0
U.S. treasury bonds \| Quoted Prices in Active Markets (Level 1) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
U.S. treasury bonds \| Significant Other Observable Inputs (Level 2) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	6,901
U.S. treasury bonds \| Significant Unobservable Inputs (Level 3) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
U.S. treasury bonds \| Carrying Amount \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	6,901
U.S. treasury bonds \| Total Fair Value \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	6,901
U.S. government agency bonds \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	1,207
Gross Unrealized Gains	2
Gross Unrealized Losses	0
Estimated Fair Value	1,209
Credit Impairment Losses	0
U.S. government agency bonds \| Quoted Prices in Active Markets (Level 1) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
U.S. government agency bonds \| Significant Other Observable Inputs (Level 2) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	1,209
U.S. government agency bonds \| Significant Unobservable Inputs (Level 3) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
U.S. government agency bonds \| Carrying Amount \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	1,209
U.S. government agency bonds \| Total Fair Value \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	1,209
International fixed income bonds \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	625
Gross Unrealized Gains	0
Gross Unrealized Losses	(1)
Estimated Fair Value	624
Credit Impairment Losses	0
International fixed income bonds \| Quoted Prices in Active Markets (Level 1) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
International fixed income bonds \| Significant Other Observable Inputs (Level 2) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	624
International fixed income bonds \| Significant Unobservable Inputs (Level 3) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
International fixed income bonds \| Carrying Amount \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	624
International fixed income bonds \| Total Fair Value \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	624
Corporate bonds \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Amortized Cost	5,134
Gross Unrealized Gains	5
Gross Unrealized Losses	(2)
Estimated Fair Value	5,137
Credit Impairment Losses	0
Corporate bonds \| Quoted Prices in Active Markets (Level 1) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Corporate bonds \| Significant Other Observable Inputs (Level 2) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	5,137
Corporate bonds \| Significant Unobservable Inputs (Level 3) \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	0
Corporate bonds \| Carrying Amount \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	5,137
Corporate bonds \| Total Fair Value \| Restricted
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	$ 5,137

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Amortized Cost, Unrealized Gains and Losses, and Estimated Fair Value of Debt Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrestricted balances	$ 101,156	$ 93,131
Deferred compensation fund	46,043	40,812
Prepaid expenses and other assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	1,400	1,500
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	45,500	40,306
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	1,933	2,007
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	47,433	42,313
Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	47,433	42,313
Municipal bonds — non-taxable
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrestricted balances		93,131
Municipal bonds — non-taxable \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrestricted balances		0
Municipal bonds — non-taxable \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrestricted balances		93,131
Municipal bonds — non-taxable \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrestricted balances		0
Municipal bonds — non-taxable \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrestricted balances		93,131
Municipal bonds — non-taxable \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrestricted balances		93,131
Money market \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Money market \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	1,933	2,007
Money market \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Money market \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	1,933	2,007
Money market \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	1,933	2,007
Commodities \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	315	298
Commodities \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Commodities \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Commodities \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	315	298
Commodities \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	315	298
Fixed income \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	4,605	4,254
Fixed income \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Fixed income \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Fixed income \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	4,605	4,254
Fixed income \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	4,605	4,254
International \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	4,942	4,621
International \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
International \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
International \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	4,942	4,621
International \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	4,942	4,621
Large cap blend \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	5,794	5,053
Large cap blend \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Large cap blend \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Large cap blend \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	5,794	5,053
Large cap blend \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	5,794	5,053
Large cap growth \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	16,890	13,886
Large cap growth \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Large cap growth \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Large cap growth \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	16,890	13,886
Large cap growth \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	16,890	13,886
Large cap value \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	6,543	5,964
Large cap value \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Large cap value \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Large cap value \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	6,543	5,964
Large cap value \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	6,543	5,964
Mid cap blend \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	3,382	3,192
Mid cap blend \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Mid cap blend \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Mid cap blend \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	3,382	3,192
Mid cap blend \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	3,382	3,192
Real estate \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	350	374
Real estate \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Real estate \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Real estate \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	350	374
Real estate \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	350	374
Small cap blend \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	2,679	2,664
Small cap blend \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Small cap blend \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	0	0
Small cap blend \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	2,679	2,664
Small cap blend \| Total Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation fund	$ 2,679	$ 2,664

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense charged against income	$ 4,597	$ 4,409
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense charged against income	4,572	4,363
Costs of services provided
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense charged against income	25	46
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense charged against income	353	463
Restricted stock, restricted stock units and deferred stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense charged against income	3,501	3,223
Performance stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense charged against income	665	565
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense charged against income	$ 78	$ 158

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ / shares in Units, shares in Thousands, $ in Millions			6 Months Ended
	Jan. 03, 2024 shares	May 30, 2023 shares	Jun. 30, 2024 USD ($) participant $ / shares shares	Jun. 30, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost \| $			$ 21.2
Period of expense of unrecognized compensation cost (in years)			3 years 3 months 18 days
Weighted average grant-date fair value of stock options granted (in dollars per share) \| $ / shares			$ 5.06	$ 6.53
SERP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance (in shares)			1,000
Remaining shares authorized for issuance (in shares)			200
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			770	500
Weighted average grant date fair value of stock granted (in dollars per share) \| $ / shares			$ 10.38	$ 13.74
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost \| $			$ 2.1
Period of expense of unrecognized compensation cost (in years)			1 year 10 months 24 days
Granted (in shares)	100		118
Weighted average grant date fair value of stock granted (in dollars per share) \| $ / shares			$ 11.85
Vesting period (in years)	3 years
DSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost \| $			$ 0.3
Period of expense of unrecognized compensation cost (in years)			10 months 24 days
Payout period (in years)			5 years
DSUs \| Non-employee member of the Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of participants electing to receive shares \| participant			3
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant (in shares)			1,800
Average weekly hours of work			20 hours
Requisite service period for plan participation eligibility			2 years
Stock options authorized to issue to employees (in shares)			4,100
Amended 2020 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares authorized under plan (in shares)		2,500
Common stock reserved for future issuance (in shares)			6,700
Shares available for future grant (in shares)			2,300
Maximum term of grants			10 years

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of Stock Options Outstanding (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of Shares
Beginning of period (in shares) \| shares	2,438
Granted (in shares) \| shares	290
Exercised (in shares) \| shares	0
Forfeited (in shares) \| shares	(1)
Expired (in shares) \| shares	(179)
End of period (in shares) \| shares	2,548
Weighted Average Exercise Price
Beginning of period (in dollars per share) \| $ / shares	$ 30.43
Granted (in dollars per share) \| $ / shares	10.36
Exercised (in dollars per share) \| $ / shares	0
Forfeited (in dollars per share) \| $ / shares	24.43
Expired (in dollars per share) \| $ / shares	28.45
End of period (in dollars per share) \| $ / shares	$ 28.29

Share-Based Compensation - Assu

Share-Based Compensation - Assumptions for Fair Value of Options Granted (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	3.90%	4%
Weighted average expected life	7 years	6 years 10 months 24 days
Expected volatility	40.50%	39.50%
Dividend yield	0%	0%

Share-Based Compensation - Summ

Share-Based Compensation - Summarized Other Information About Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Outstanding:
Aggregate intrinsic value	$ 64
Weighted average remaining contractual life	4 years 10 months 24 days
Exercisable:
Number of options (in shares) \| shares	1,756
Weighted average exercise price (in dollars per share) \| $ / shares	$ 33.93
Aggregate intrinsic value	$ 0
Weighted average remaining contractual life	3 years 4 months 24 days

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of Restricted Stock Units (Details) - RSUs - $ / shares shares in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Number
Beginning balance (in shares)	1,102
Granted (in shares)	770	500
Vested (in shares)	(297)
Forfeited (in shares)	(17)
Ending balance (in shares)	1,558
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 18.57
Granted (in dollars per share)	10.38	$ 13.74
Vested (in dollars per share)	21.68
Forfeited (in dollars per share)	14.17
Ending balance (in dollars per share)	$ 13.97

Share-Based Compensation - Sc_4

Share-Based Compensation - Schedule of Outstanding Performance Stock Units (Details) - PSUs - $ / shares shares in Thousands		6 Months Ended
	Jan. 03, 2024	Jun. 30, 2024
Number
Beginning balance (in shares)		175
Granted (in shares)	100	118
Vested (in shares)		0
Forfeited (in shares)		(35)
Ending balance (in shares)		258
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)		$ 21.52
Granted (in dollars per share)		11.85
Vested (in dollars per share)		0
Forfeited (in dollars per share)		34.52
Ending balance (in dollars per share)		$ 15.31

Share-Based Compensation - Opti

Share-Based Compensation - Options Granted Under Employee Stock Purchase Plan (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	3.90%	4%
Weighted average expected life (years)	7 years	6 years 10 months 24 days
Expected volatility	40.50%	39.50%
Dividend yield	0%	0%
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	4.80%	4.80%
Weighted average expected life (years)	1 year	1 year
Expected volatility	37.10%	42.90%
Dividend yield	0%	7.10%

Share-Based Compensation - Supp

Share-Based Compensation - Supplemental Employee Retirement Plan (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
SERP expense	$ 4,597	$ 4,409
SERP
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
SERP expense	355	298
Unrealized gain recorded in SERP liability account	$ 5,350	$ 3,871

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Impact of discrete tax items	$ 1,200,000	$ 1,100,000
Unrecognized tax benefits	$ 0

Segment Information - Schedule

Segment Information - Schedule of Segment Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) segment	Jun. 30, 2023 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment			2
Segment Reporting Information [Line Items]
Revenues	$ 426,288	$ 418,931	$ 849,721	$ 836,161
Income before income taxes	(1,986)	10,934	19,328	27,089
Corporate and eliminations
Segment Reporting Information [Line Items]
Income before income taxes	(33,935)	(18,117)	(48,690)	(36,682)
Housekeeping
Segment Reporting Information [Line Items]
Revenues	191,006	190,817	381,565	384,336
Housekeeping \| Operating segments
Segment Reporting Information [Line Items]
Income before income taxes	17,017	16,608	35,459	36,661
Dietary
Segment Reporting Information [Line Items]
Revenues	235,282	228,114	468,156	451,825
Dietary \| Operating segments
Segment Reporting Information [Line Items]
Income before income taxes	$ 14,932	$ 12,443	$ 32,559	$ 27,110

Basic (Loss) Earnings Per Com_3

Basic (Loss) Earnings Per Common Share - Schedule of Weighted Average Basic and Diluted Common Shares Outstanding (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator for basic and diluted (loss) earnings per share:
Net (loss) income	$ (1,788)	$ 15,309	$ 8,254	$ 11,671	$ 13,521	$ 19,925
Denominator
Weighted average number of common shares outstanding - basic (in shares)	73,853		74,478		73,889	74,488
Effect of dilutive securities (in shares)	0		89		159	55
Weighted average number of common shares outstanding - diluted (in shares)	73,853		74,567		74,048	74,543
Basic (loss) earnings per share (in dollars per share)	$ (0.02)		$ 0.11		$ 0.18	$ 0.27
Diluted (loss) earnings per share (in dollars per share)	$ (0.02)		$ 0.11		$ 0.18	$ 0.27

Basic (Loss) Earnings Per Com_4

Basic (Loss) Earnings Per Common Share - Schedule Anti-dilutive Outstanding Equity Awards Under Share Based Compensation Plans (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Anti-dilutive (in shares)	3,000	3,077	2,844	2,721

Other Contingencies (Details)

Other Contingencies (Details)	6 Months Ended
Other Contingencies (Details)	Jun. 30, 2024 USD ($) covenant	Dec. 31, 2023 USD ($)
Short-term Debt [Line Items]
Bank line of credit	$ 300,000,000
Basis spread on variable rate	1.65%
Long-term line of credit	$ 30,000,000	$ 25,000,000
Financial covenants \| covenant	2
Reduction of bank line of credit	$ 60,200,000
Amount available under line of credit	209,800,000
Irrevocable standby letters of credit
Short-term Debt [Line Items]
Irrevocable standby letter of credit, outstanding	$ 60,200,000